<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">98023</article-id><article-id pub-id-type="doi">10.7554/eLife.98023</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.98023.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Dynamics of compartment-specific proteomic landscapes of hepatotoxic and cholestatic models of liver fibrosis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Jirouskova</surname><given-names>Marketa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0004-7173-2177</contrib-id><email>marketa.jirouskova@img.cas.cz</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Harant</surname><given-names>Karel</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Cejnar</surname><given-names>Pavel</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ojha</surname><given-names>Srikant</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Korelova</surname><given-names>Katerina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sarnova</surname><given-names>Lenka</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sticova</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mayr</surname><given-names>Christoph H</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Schiller</surname><given-names>Herbert B</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Gregor</surname><given-names>Martin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6841-9527</contrib-id><email>martin.gregor@img.cas.cz</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/045syc608</institution-id><institution>Laboratory of Integrative Biology, Institute of Molecular Genetics of the Czech Academy of Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Prague</named-content></addr-line><country>Czech Republic</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/024d6js02</institution-id><institution>Laboratory of Mass Spectrometry, BIOCEV, Faculty of Science, Charles University</institution></institution-wrap><addr-line><named-content content-type="city">Prague</named-content></addr-line><country>Czech Republic</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05ggn0a85</institution-id><institution>Department of Mathematics, Informatics and Cybernetics, University of Chemistry and Technology</institution></institution-wrap><addr-line><named-content content-type="city">Prague</named-content></addr-line><country>Czech Republic</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/024d6js02</institution-id><institution>Department of Animal Physiology, Faculty of Science, Charles University</institution></institution-wrap><addr-line><named-content content-type="city">Prague</named-content></addr-line><country>Czech Republic</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036zr1b90</institution-id><institution>Clinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Prague</named-content></addr-line><country>Czech Republic</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04sg4ka71</institution-id><institution>Department of Pathology, The Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady</institution></institution-wrap><addr-line><named-content content-type="city">Prague</named-content></addr-line><country>Czech Republic</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dx11k66</institution-id><institution>Helmholtz Munich, Research Unit Precision Regenerative Medicine; Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL)</institution></institution-wrap><addr-line><named-content content-type="city">Munich</named-content></addr-line><country>Germany</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05591te55</institution-id><institution>Institute of Experimental Pneumology, LMU University Hospital, Ludwig-Maximilians University</institution></institution-wrap><addr-line><named-content content-type="city">Munich</named-content></addr-line><country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Mistry</surname><given-names>Pramod K</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Mistry</surname><given-names>Pramod K</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>08</day><month>04</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP98023</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-04-21"><day>21</day><month>04</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-03-28"><day>28</day><month>03</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.03.26.586230"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-11-13"><day>13</day><month>11</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.98023.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-02-28"><day>28</day><month>02</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.98023.2"/></event></pub-history><permissions><copyright-statement>© 2024, Jirouskova et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Jirouskova et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-98023-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-98023-figures-v1.pdf"/><abstract><p>Accumulation of extracellular matrix (ECM) in liver fibrosis is associated with changes in protein abundance and composition depending upon etiology of the underlying liver disease. Current efforts to unravel etiology-specific mechanisms and pharmacological targets rely on several models of experimental fibrosis. Here, we characterize and compare dynamics of hepatic proteome remodeling during fibrosis development and spontaneous healing in experimental mouse models of hepatotoxic (carbon tetrachloride [CCl<sub>4</sub>] intoxication) and cholestatic (3,5-diethoxycarbonyl-1,4-dihydrocollidine [DDC] feeding) injury. Using detergent-based tissue extraction and mass spectrometry, we identified compartment-specific changes in the liver proteome with detailed attention to ECM composition and changes in protein solubility. Our analysis revealed distinct time-resolved CCl<sub>4</sub> and DDC signatures, with identified signaling pathways suggesting limited healing and a potential for carcinogenesis associated with cholestasis. Correlation of protein abundance profiles with fibrous deposits revealed extracellular chaperone clusterin with implicated role in fibrosis resolution. Dynamics of clusterin expression was validated in the context of human liver fibrosis. Atomic force microscopy of fibrotic livers complemented proteomics with profiles of disease-associated changes in local liver tissue mechanics. This study determined compartment-specific proteomic landscapes of liver fibrosis and delineated etiology-specific ECM components, providing thus a foundation for future antifibrotic therapies.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Alcoholism or chronic conditions like hepatitis damage the liver. Over time, scar tissue builds up in the liver, causing cirrhosis. The scaring results from the liver’s repeated attempts to repair itself by creating more structural proteins called extracellular matrix proteins. A buildup of these scaffolding proteins leads to tissue stiffening or fibrosis. Fibrosis may heal in some cases but in others, it may progress to cirrhosis, liver cancer or liver failure.</p><p>Learning more about these processes may help scientists and clinicians understand why fibrosis is reversible in some cases but not others. It may also allow them to develop treatments that can treat or reverse fibrosis and prevent cirrhosis, liver cancer, or liver failure. The first step is studying how fibrosis occurs in mouse models that mimic different types of liver disease. For example, repetitive ingestion of a toxic substance, such as alcohol, can cause one type of liver disease. However, slowing or stalling bile flow through the biliary system (the liver, gallbladder, and bile ducts), leads to a different type of chronic liver injury.</p><p>Jirouskova et al. identify an extracellular protein called clusterin that may help heal fibrosis. The experiments used mouse models of two different types of liver disease. One mimicked liver disease caused by repetitive toxin injury, and the other modelled liver disease caused by chronic stalling of the bile flow in the liver (cholestasis). In the experiments, Jirouskova et al. looked at all the proteins made in each type of liver disease as the animals developed fibrosis or their fibrosis resolved. They also studied extracellular matrix proteins and how they affected molecular signaling in the liver tissue. The experiments revealed different patterns of protein production and healing in the different types of liver disease. The animals with liver diseases caused by chronic cholestatic injury were less likely to heal their livers and showed potential to progress to liver cancer. Production of the clusterin protein was connected with better liver recovery from toxic injuries.</p><p>Jirouskova et al. provide a comprehensive map of all the proteins produced over the course of liver fibrosis progression and healing in two different animal models of liver disease. Scientists and clinicians may use this information to study liver disease types. It may also one day help them personalize patient's therapies. The experiments show that extracellular matrix proteins are essential contributors to fibrosis and key signaling agents in liver disease. This may make them good targets for new therapies. Boosting clusterin production may be one approach to promoting liver recovery. More studies are needed to confirm this before such therapies can be developed and tested in humans.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>mass spectrometry</kwd><kwd>matrisome</kwd><kwd>collagen deposits</kwd><kwd>atomic force microscopy</kwd><kwd>clusterin</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001824</institution-id><institution>Grantová Agentura České Republiky</institution></institution-wrap></funding-source><award-id>18-02699S</award-id><principal-award-recipient><name><surname>Jirouskova</surname><given-names>Marketa</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001824</institution-id><institution>Grantová Agentura České Republiky</institution></institution-wrap></funding-source><award-id>21-21736S</award-id><principal-award-recipient><name><surname>Gregor</surname><given-names>Martin</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001823</institution-id><institution>Ministerstvo Školství, Mládeže a Tělovýchovy</institution></institution-wrap></funding-source><award-id>NU21-04-00100</award-id><principal-award-recipient><name><surname>Gregor</surname><given-names>Martin</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001823</institution-id><institution>Ministerstvo Školství, Mládeže a Tělovýchovy</institution></institution-wrap></funding-source><award-id>RVO 68378050</award-id><principal-award-recipient><name><surname>Gregor</surname><given-names>Martin</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000780</institution-id><institution>NextGenerationEU</institution></institution-wrap></funding-source><award-id>LX22NPO5102</award-id><principal-award-recipient><name><surname>Gregor</surname><given-names>Martin</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007543</institution-id><institution>Grantová Agentura, Univerzita Karlova</institution></institution-wrap></funding-source><award-id>273723</award-id><principal-award-recipient><name><surname>Ojha</surname><given-names>Srikant</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001823</institution-id><institution>Ministerstvo Školství, Mládeže a Tělovýchovy</institution></institution-wrap></funding-source><award-id>LM2023050</award-id><principal-award-recipient><name><surname>Gregor</surname><given-names>Martin</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001823</institution-id><institution>Ministerstvo Školství, Mládeže a Tělovýchovy</institution></institution-wrap></funding-source><award-id>LM2018126</award-id><principal-award-recipient><name><surname>Gregor</surname><given-names>Martin</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001823</institution-id><institution>Ministerstvo Školství, Mládeže a Tělovýchovy</institution></institution-wrap></funding-source><award-id>LQ1604 NPU II</award-id><principal-award-recipient><name><surname>Gregor</surname><given-names>Martin</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001823</institution-id><institution>Ministerstvo Školství, Mládeže a Tělovýchovy</institution></institution-wrap></funding-source><award-id>LO1419</award-id><principal-award-recipient><name><surname>Gregor</surname><given-names>Martin</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001823</institution-id><institution>Ministerstvo Školství, Mládeže a Tělovýchovy</institution></institution-wrap></funding-source><award-id>LM2015040</award-id><principal-award-recipient><name><surname>Gregor</surname><given-names>Martin</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A comprehensive proteomic map of liver fibrosis progression and healing in two mouse models identifies etiology-specific extracellular matrix components, laying the foundation for targeted antifibrotic therapies.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Liver fibrosis and subsequent cirrhosis, two leading causes of liver disease-related deaths worldwide (<xref ref-type="bibr" rid="bib28">Karlsen et al., 2022</xref>), develop as a result of chronic liver injury of multiple etiologies (<xref ref-type="bibr" rid="bib30">Kisseleva and Brenner, 2021</xref>). Fibrosis is characterized by excessive accumulation of extracellular matrix (ECM) proteins forming fibrous scar tissue. In the liver, such pathological matrix is deposited by activated hepatic stellate cells (HSCs) and/or portal fibroblasts (PFs) in response to the inflammatory reaction (<xref ref-type="bibr" rid="bib30">Kisseleva and Brenner, 2021</xref>; <xref ref-type="bibr" rid="bib20">Henderson et al., 2020</xref>). Recent multi-omics studies have framed fibrosis as a dynamic multicellular process associated with the remodeling of gene expression landscapes (<xref ref-type="bibr" rid="bib51">Ramachandran et al., 2019</xref>) and profound changes in liver protein abundance as well as composition (<xref ref-type="bibr" rid="bib45">Niu et al., 2022</xref>; <xref ref-type="bibr" rid="bib38">Massey et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Klaas et al., 2016</xref>).</p><p>Hepatocellular injury alters parenchymal mechanical properties (<xref ref-type="bibr" rid="bib17">Georges et al., 2007</xref>), thus further facilitating activation of resident HSCs and PFs and their differentiation into myofibroblasts depositing collagen-rich ECM (<xref ref-type="bibr" rid="bib47">Olsen et al., 2011</xref>). Accumulation of abnormal ECM further promotes ECM-depositing myofibroblasts and fosters progressive whole-organ stiffening as a result of ongoing fibrogenesis (<xref ref-type="bibr" rid="bib54">Saneyasu et al., 2016</xref>). Thus, ECM-associated changes are increasingly perceived as causative, rather than consequential, and multiple efforts have focused on the identification of extracellular niche components that drive the pathogenesis of fibrosis (<xref ref-type="bibr" rid="bib55">Schiller et al., 2015</xref>).</p><p>The ECM is a complex network of hundreds of proteins acting as a three-dimensional scaffold, supporting cells mechanically and functioning as a reservoir for secreted factors (e.g. growth factors and cytokines) (<xref ref-type="bibr" rid="bib24">Hynes, 2009</xref>). This so-called ‘matrisome’ consists of ‘core matrisome’ (the structural components of the ECM, i.e. collagens, glycoproteins, and proteoglycans) and ‘matrix-associated matrisome’ (the ECM-interacting proteins) (<xref ref-type="bibr" rid="bib42">Naba et al., 2012</xref>). Transitions of extracellular factors between the insoluble matrisome and the soluble pools modulate their signaling capabilities and bioavailability (<xref ref-type="bibr" rid="bib55">Schiller et al., 2015</xref>). As fibrous ECM assemblies also determine tissue mechanics, matrisome constituents provide matrix-embedded cells with spatially distinct biochemical and biomechanical context.</p><p>In terms of etiology, chronic liver injury is inflicted either by hepatotoxic or by cholestatic insult (<xref ref-type="bibr" rid="bib30">Kisseleva and Brenner, 2021</xref>). In recent decades, several corresponding animal models of liver fibrosis have been established (<xref ref-type="bibr" rid="bib35">Liu et al., 2013</xref>). Despite several translational limitations (<xref ref-type="bibr" rid="bib62">Trautwein et al., 2015</xref>), these experimental models mimic fundamental aspects of human liver fibrosis (<xref ref-type="bibr" rid="bib35">Liu et al., 2013</xref>). Thus, frequently used iterative carbon tetrachloride (CCl<sub>4</sub>) intoxication causes hepatocellular damage, HSC activation, and development of pericentral liver fibrosis that evolves into severe bridging fibrosis (<xref ref-type="bibr" rid="bib35">Liu et al., 2013</xref>). In contrast, 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) feeding induces obstructive cholestasis, characterized by expansion of PFs and consecutive periportal fibrosis with typical portal-portal septa (<xref ref-type="bibr" rid="bib15">Fickert et al., 2007</xref>). As both human and animal studies have shown that liver fibrosis can be ameliorated by either targeting progression or promoting resolution (<xref ref-type="bibr" rid="bib62">Trautwein et al., 2015</xref>), experimental models have become instrumental for identifying factors and mechanisms central to blocking fibrosis progression and promoting the reversal of advanced fibrosis.</p><p>In this comparative study, we employed CCl<sub>4</sub>- and DDC-based mouse models to describe proteomic changes during liver injury, fibrosis development, and repair while focusing on matrisome remodeling and associated alterations in tissue biomechanics. Our in-depth analysis of mass spectrometry (MS) data obtained from total liver lysates and ECM-enriched insoluble fractions defines compartment- and time-resolved proteomic signatures in hepatotoxin- vs. cholestasis-induced fibrosis and healing and delineates disease-specific matrisome.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Proteomic analysis outlines the gradual fibrosis development and partial healing in both CCl<sub>4</sub>- and DDC-induced liver injury</title><p>To compare time-resolved, compartment-specific proteomes of CCl<sub>4</sub>- and DDC-induced models of liver fibrosis, total liver lysates (Total) together with two protein fractions obtained by one-step detergent extraction (ECM-enriched insoluble fraction [E-fraction] and soluble fraction [S-fraction]) were prepared for MS analysis (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The gradual fibrogenesis was assessed at two time points (T1 and T2) corresponding to mild fibrosis with partially bridging septa (T1, 3 weeks for CCl<sub>4</sub> and 2 weeks for DDC treatment) and advanced fibrosis (T2, 6 weeks for CCl<sub>4</sub> and 4 weeks for DDC). To characterize the dynamics of spontaneous fibrosis resolution, we allowed the mice 5 (T3) or 10 days (T4) to recover. Both models developed typical progressive liver damage with fibrotic scarring followed by partial healing upon insult withdrawal as demonstrated by plasma levels of liver injury markers and the extent of collagen-rich deposits in liver sections (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Hepatotoxic and cholestatic injury generate distinct time-resolved and compartment-specific protein signatures.</title><p>(<bold>A</bold>) Schematic overview of the experimental setup. Six animals were used in each model at each time point. (<bold>B</bold>) Numbers of quantified proteins at the indicated time points and experimental conditions; n=6. (<bold>C</bold>) Box plot shows the distribution of protein sequence coverage (coverage of possible tryptic peptides per protein in %) for the indicated matrisome categories (as defined by <xref ref-type="bibr" rid="bib42">Naba et al., 2012</xref>) and all detected proteins in experimental conditions indicated. (<bold>D</bold>) Principal component analysis (PCA) of Total proteome separates time-dependent fibrogenesis and healing in carbon tetrachloride (CCl<sub>4</sub>)- (closed symbols) and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)- (open symbols) induced fibrosis. The first two components of data variability of 3624 proteins identified in Total liver fractions in CCl<sub>4</sub> and 3521 proteins in DDC are shown; n=6. (<bold>E</bold>) PCA shows the separation of Total (closed symbols) and E-fraction (open symbols) proteomes in time; the first two components of data variability are shown; n=6. (<bold>F</bold>) Line plots show time-dependent changes in mass spectrometry (MS) intensities in Total (solid line) and E-fraction (broken line) proteomes for indicated selected proteins in CCl<sub>4</sub> and DDC models; n=4–6.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Liver damage markers and collagen deposits in carbon tetrachloride (CCl<sub>4</sub>) and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) models.</title><p>(<bold>A</bold>) Serum levels of alanine aspartate transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and bilirubin determined from CCl<sub>4</sub>- and DDC-treated mice at indicated time points. (<bold>B</bold>) Representative images of Sirius red (SR)-stained liver sections from mice treated with CCl<sub>4</sub> or DDC document time course in fibrosis development and partial resolution. Scale bar = 50 μm. Line plot shows the quantification of collagen deposits in each time point shown as a percentage of the SR<sup>+</sup> area per liver section; n=6.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Hierarchical cluster analysis shows the separation of carbon tetrachloride (CCl<sub>4</sub>)- and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-derived Total proteomes.</title><p>Unsupervised hierarchical clustering of z-scored mass spectrometry intensities (log 2) of proteins from Total CCl<sub>4</sub> and DDC proteomes. UniProtKB keyword enrichment annotations for clusters of proteins (Benjamini-Hochberg false discovery rate &lt;0.04) are shown (extracellular matrix [ECM]-related keywords in blue).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig1-figsupp2-v1.tif"/></fig></fig-group><p>Using the two models, we quantified 4734 proteins approximately evenly distributed across all time points and fractions (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The numbers of quantified proteins were comparable across time and treatments with proteins equally represented in each of the cohorts. No bias was shown against any of the analyzed cohorts or time points (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Likewise, the numbers of quantified proteins across fractions showed only minor variability (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). We identified 184 matrisome constituents (<xref ref-type="bibr" rid="bib42">Naba et al., 2012</xref>; <xref ref-type="bibr" rid="bib58">Shao et al., 2020</xref>) among the quantified proteins. Their median sequence coverage in controls, CCl<sub>4</sub>, and DDC samples only slightly differed from sequence coverage of all identified proteins, showing no strong bias against matrisome-annotated proteins (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Principal component analysis (PCA) revealed clear temporal separation of CCl<sub>4</sub>- and DDC-derived samples in both Total and E-fraction (<xref ref-type="fig" rid="fig1">Figure 1D and E</xref>). Samples also separated in time, which demonstrated fibrosis development and its partial resolution for Total and E-fraction samples in both models (<xref ref-type="fig" rid="fig1">Figure 1E</xref>).</p><p>Unsupervised hierarchical cluster analysis of total lysate proteins together with annotation enrichment of the observed clusters demonstrated substantial differences in the dynamic regulation of protein expression between the two models (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). This was evidenced by differential Total MS protein intensity temporal profiles of matrisome-enriched cluster constituents, such as vitronectin (VTN), galectin 8 (LGALS8), fibrillin 1 (FBN1), or a putative portal myofibroblast marker collagen type XV α-1 chain (COL15A1; <xref ref-type="fig" rid="fig1">Figure 1F</xref>). Moreover, distinct galectin 8 and vitronectin expression profiles obtained for CCl<sub>4</sub> and DDC E-fractions revealed complex changes in protein association with the insoluble proteome. Taken together, our MS data allow for time-resolved identification of proteins differentially expressed during fibrosis progression and resolution in etiologically distinct models of liver fibrosis. Moreover, this approach enables analysis of complex changes in the solubility of the identified proteins and their transition between liver compartments.</p></sec><sec id="s2-2"><title>Time-resolved analysis of Total proteomes indicates limited healing and potential tumorigenicity in the DDC model</title><p>To capture the proteome differences between hepatotoxin- vs. cholestasis-induced fibrogenesis, we determined proteins significantly regulated during fibrogenesis separately in CCl<sub>4</sub> and DDC Total samples (Benjamini-Hochberg false discovery rate [BH FDR]&lt;5%; see Materials and methods). In total, 762 proteins were found to be shared by the two models, while 514 (CCl<sub>4</sub>) and 1074 (DDC) proteins were identified as unique for the respective model (<xref ref-type="fig" rid="fig2">Figure 2A</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Time-resolved analysis of Total proteomes shows limited healing in matrisome-enriched protein clusters in the cholestatic model.</title><p>(<bold>A</bold>) Venn diagram shows relative proportion of 1276 and 1836 proteins differentially expressed (t-test; Benjamini-Hochberg false discovery rate [BH FDR]&lt;5%) in Total carbon tetrachloride (CCl<sub>4</sub>) and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) proteomes, respectively. (<bold>B</bold>) Hierarchical cluster analysis of the activity score of the upstream regulators at the indicated time points predicted by Ingenuity Pathway Analysis (IPA) from unique CCl<sub>4</sub> and DDC protein signatures shown in A. (<bold>C, D</bold>) Hierarchical clustering of mean <italic>z</italic>-scored mass spectrometry (MS) intensities of proteins of Total CCl<sub>4</sub> (C) or DDC (D) proteomes; n=6. Profiles of <italic>z</italic>-scored MS intensities of proteins from matrisome-annotated clusters for CCl<sub>4</sub> (I–III) and DDC (I and II) models are shown. (<bold>E</bold>) Venn diagram compares proteins from matrisome-annotated clusters shown in C and D. UniProt keyword enrichment annotation for each group within the diagram is indicated (Fisher’s test, BH FDR&lt;4%).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Ingenuity Pathway Analysis (IPA) of upstream regulators and canonical signaling pathways in carbon tetrachloride (CCl<sub>4</sub>) and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) models.</title><p>(<bold>A</bold>) Hierarchical cluster analysis of the activity score of the upstream regulators and downstream canonical signaling pathways at the indicated time points predicted by IPA from 762 proteins shared between CCl<sub>4</sub> and DDC protein signatures as shown in <xref ref-type="fig" rid="fig2">Figure 2A</xref>. (<bold>B</bold>) Hierarchical cluster analysis of the activity score of the canonical signaling pathways at the indicated time points predicted by IPA from proteins uniquely identified in CCl<sub>4</sub> (514) and DDC (1074) Total proteomes. (<bold>C</bold>) Venn diagram compares proteins from matrisome-annotated clusters as shown in <xref ref-type="fig" rid="fig2">Figure 2A</xref>. Top canonical signaling pathways identified by IPA are shown. (<bold>D</bold>) Venn diagram compares proteins identified as newly induced by fibrosis development in CCl<sub>4</sub> and DDC models, highlighting thus qualitative changes in total proteomes induced by fibrogenesis. We identified 65 newly induced proteins in CCl<sub>4</sub>- and 118 in DDC-treated livers. Top canonical signaling pathways identified by IPA associated with CCl<sub>4</sub>-induced proteins and selected matrisome-annotated proteins are shown. Matrisome proteins are highlighted with color coding to indicate identified matrisome categories.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Collagens and laminins identified in Total proteomes.</title><p>The line plots show the time-dependent change in mass spectrometry intensities of indicated selected collagens and laminins in Total (solid line) and E-fraction (broken line) proteomes in carbon tetrachloride (CCl<sub>4</sub>) and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) models; n=4–6.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig2-figsupp2-v1.tif"/></fig></fig-group><p>Using Ingenuity Pathway Analysis (IPA), we predicted upstream transcriptional regulators and growth factors together with corresponding downstream biological signaling pathways differentially associated with identified protein groups (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Abundance changes in known targets indicated the activity of key regulators involved in fibrogenesis (transforming growth factor beta-1 [TGFB1] and angiotensinogen [AGT]), hypoxia response (hypoxia-inducible factor 1-alpha [HIF1A]), and inhibition of factors mediating hepatocyte function (hepatocyte nuclear factor 4-alpha [HNF4A] and 1-alpha [HNF1A]) or involved in HSC inactivation (peroxisome proliferator-activated receptor gamma coactivator 1-alpha [PPARGC1A]) in both fibrotic models (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Interestingly, the pro-proliferative mammalian target of rapamycin (mTOR) pathway showed signaling attenuation in the course of CCl<sub>4</sub> treatment but upregulation in the case of DDC treatment, suggesting hyperplastic potential of the DDC model (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Consistently, analysis of the DDC signature revealed inhibition of tumor suppressor gene <italic>Rb1</italic> with simultaneous activation of potential oncogenic regulators lysine demethylase 5A (KDM5A), myocardin-related transcription factor A (MRTFA), myelocytomatosis oncogene (MYC), and yes-associated protein (YAP), thus underscoring a potential carcinogenic risk of cholestatic model (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). By contrast, the CCl<sub>4</sub> signature indicated activation of epidermal growth factor (EGF) and vascular endothelial growth factor A (VEGFA) with simultaneous downregulation of the HNF4A (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), thus supporting previous reports on the importance of these factors during hepatotoxic injury (<xref ref-type="bibr" rid="bib32">Kömüves et al., 2000</xref>; <xref ref-type="bibr" rid="bib67">Yang et al., 2014</xref>; <xref ref-type="bibr" rid="bib69">Yue et al., 2010</xref>). While dynamic changes of regulatory networks and signaling pathways correlated well with fibrosis progression in both models, ineffective downregulation of profibrotic signaling in the DDC-induced model suggested a limited capacity of the liver to heal from cholestatic injury (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><p>Next, we analyzed CCl<sub>4</sub> and DDC Total proteomes using unsupervised hierarchical clustering and functional annotation term enrichment (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>). This allowed the separation of proteins with similar temporal abundance profiles while simultaneously revealing clusters comprising matrisome-annotated proteins (see Materials and methods). In the CCl<sub>4</sub> proteome, three matrisome-annotated clusters (<xref ref-type="fig" rid="fig2">Figure 2C</xref>; clusters I, II, and III) containing 755 proteins showed a variable degree of time-dependent abundance decline over the course of healing. By contrast, two large matrisome-annotated clusters (<xref ref-type="fig" rid="fig2">Figure 2D</xref>; clusters I and II) with 799 constituents showed almost no decline in abundance over the recovery period in the DDC model. Our data reflect the reversibility of CCl<sub>4</sub>-induced fibrogenesis and restricted capacity to heal with higher potential of carcinogenic risk in the DDC model.</p></sec><sec id="s2-3"><title>Matrisome linked with cholestasis is enriched in basement membrane proteins whereas deposits upon hepatotoxic injury contain matrisome-associated proteins</title><p>To further dissect disease-specific processes associated with matrisome-enriched clusters (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>), we followed the functional annotation of proteins using a comprehensive annotation matrix compiled from Gene Ontology terms, UniProtKB keywords, and the MatrisomeDB matrisome database (<xref ref-type="bibr" rid="bib42">Naba et al., 2012</xref>; <xref ref-type="bibr" rid="bib58">Shao et al., 2020</xref>). This revealed that 303 proteins shared by CCl<sub>4</sub> and DDC Total proteomes were annotated not only with matrisome-related keywords but also as ‘cell adhesion’, ‘fibrinogen complex’, ‘platelet aggregation’, and ‘intermediate filaments’, thus indicating engagement in cellular interaction with ECM (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Consistently, top canonical IPA pathways included ‘signaling by Rho family GTPases’, ‘integrin signaling’, and ‘actin cytoskeleton signaling’ (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). As anticipated, 452 proteins uniquely identified in CCl<sub>4</sub> matrisome-enriched clusters were also associated with inflammatory response, a well-described feature of this model (<xref ref-type="bibr" rid="bib18">Ghallab et al., 2019</xref>). A group of 496 proteins exclusive for DDC was found to associate with ‘basement membrane‘ (BM) and ‘cell substrate junction’ reflecting an increased abundance of BM components synthesized during the development of periductal fibrosis (e.g. laminins, α-chains of collagen types IV, VI, and XVIII; <xref ref-type="fig" rid="fig2">Figure 2E</xref>).</p><p>Within a group of 60 matrisome proteins significantly changing in both Total CCl<sub>4</sub> and DDC proteomes (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), there were mainly core matrisome proteins, such as collagens (e.g. α-chains of collagen types I and V) and ECM glycoproteins (e.g. fibronectin, EMILIN1, and vitronectin). In contrast to previous reports (<xref ref-type="bibr" rid="bib31">Klaas et al., 2016</xref>), we found collagen type VI, a protein regulating ECM contractility (<xref ref-type="bibr" rid="bib64">Williams et al., 2020</xref>), upregulated during fibrogenesis in both models (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). In addition, we identified several matrisome-associated proteins (e.g. NGLY1, PLOD3, S100A4, MUG2, SERPINA7, SERPINF1, and P4HA1) not previously reported in liver fibrosis as uniquely induced in the CCl<sub>4</sub> model (<xref ref-type="bibr" rid="bib58">Shao et al., 2020</xref>). Among these, ECM glycoprotein lactadherin (MFGE8) has been shown to reduce liver fibrosis in mice (<xref ref-type="bibr" rid="bib3">An et al., 2017</xref>). In contrast, BM matrisome proteins, such as laminins, collagen types IV and XVIII, and perlecan (HSPG2), were exclusively upregulated in the DDC proteome (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Comparison of matrisome proteins differentially expressed between the carbon tetrachloride (CCl<sub>4</sub>)- and 3,5-diethoxycarbonyl-1,4-dihy- drocollidine (DDC)-derived Total proteomes with immunofluorescence (IF) localization of the main core matrisome proteins within the injured livers.</title><p>(<bold>A</bold>) Venn diagram shows a comparison of matrisome proteins differentially enriched in Total CCl<sub>4</sub> and DDC proteomes. Color coding indicates identified matrisome categories. (<bold>B–D</bold>) Representative IF images of collagen type I (B), fibronectin (C), and collagen type IV (D), all in green in liver sections from untreated controls (Ctrl), CCl<sub>4</sub>-, and DDC-treated mice at time points of fibrosis development (T2) and resolution (T4). Bile ducts were visualized with antibodies to keratin 19 (K19; red); nuclei were stained with DAPI (blue). CV, central vein; PV, portal vein. Scale bar = 100 μm. Line plots show time-dependent change in respective mass spectrometry (MS) intensities in Total (solid line) and E-fraction (broken line) proteomes in CCl<sub>4</sub> and DDC models; n=4–6.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig3-v1.tif"/></fig><p>To validate our findings demonstrating distinct features of the fibrotic models used, we performed immunofluorescence (IF) analysis of major core matrisome proteins abundantly upregulated in both CCl<sub>4</sub> and DDC proteomes (<xref ref-type="fig" rid="fig3">Figure 3B–D</xref>). Collagen type I accumulated at the sites of primary injury and, consistent with proteomics, was only partially reduced upon recovery in the DDC model (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Collagen type I-rich areas were delineated by fibronectin, a protein serving as a scaffold for collagen fibril assembly (<xref ref-type="bibr" rid="bib60">Sottile et al., 2007</xref>). Although fibronectin abundance in Total CCl<sub>4</sub> and DDC proteomes decreased with healing, IF analysis revealed persisting deposits within capillarized hepatic sinusoids even after a recovery period of 10 days (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Consistent with a report on human cirrhotic livers (<xref ref-type="bibr" rid="bib36">Mak et al., 2013</xref>), BM-associated collagen type IV accumulated around fibrotic septa in both models and its persistent presence indicated incomplete liver healing after DDC withdrawal (<xref ref-type="fig" rid="fig3">Figure 3D</xref>).</p><p>To analyze proteins that are induced during fibrosis development in Total proteome, we identified proteins detected in T2 and T1 but not in control samples in each model. This way we identified 65 newly induced proteins in CCl<sub>4</sub>- and 118 in DDC-treated livers. These were mainly matrisome proteins and proteins of the immune defense response (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). Notably, we found lysyl hydroxylase (Plod3), a matrisome protein highly expressed in activated HSCs (<xref ref-type="bibr" rid="bib44">Nishio et al., 2019</xref>), among newly expressed CCl<sub>4</sub>-specific proteins. In contrast, DDC-specific matrisomal proteins included elastin (ELN), a proposed PF marker (<xref ref-type="bibr" rid="bib68">Yang et al., 2021</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). This confirmed the specificity of identified CCl<sub>4</sub> and DDC signatures and suggested the potential of our approach in describing the different origin of collagen-producing myofibroblasts in analyzed models.</p></sec><sec id="s2-4"><title>Integrin αv is specifically induced on the membranes of injured hepatocytes within fibrotic scar tissue in the hepatotoxic CCl<sub>4</sub> model</title><p>The dynamic nature of fibrosis stems from interplay between injured hepatocytes, immune cells, and hepatic myofibroblasts (<xref ref-type="bibr" rid="bib20">Henderson et al., 2020</xref>). Using previously published cell-type-specific signatures (see Materials and methods), we identified 10 different cell populations in CCl<sub>4</sub> and DDC samples and compared their abundances over the course of liver fibrosis (<xref ref-type="fig" rid="fig4">Figure 4A–D</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). A set of 18 proteins quantified from the signature of hepatocytes exhibited faster decline in the hepatotoxic CCl<sub>4</sub> than DDC model (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), corresponding well to the extensive parenchymal injury evidenced by high alanine and aspartate transaminase levels (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). In support, large areas of injured pericentral hepatocytes were found negative for HNF4α staining in CCl<sub>4</sub> model (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>). Rapid increase in HSC and activated PF signatures paralleled the activation and proliferation of ECM-depositing myofibroblasts in both fibrotic models (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) evidenced by IF staining of myofibroblast marker alpha smooth muscle actin (αSMA; <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>). However, faster upregulation of activated PFs in DDC confirms their predominant role in cholestatic fibrosis. Temporal abundance profiles of Kupffer cell, macrophage, monocyte, and B-cell signature proteins illustrate faster recovery from inflammation with healing in the CCl<sub>4</sub> than in DDC model (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). This was further confirmed by IF staining of liver sections (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>). These findings, together with matrisome-enriched protein cluster analysis (<xref ref-type="fig" rid="fig2">Figure 2E</xref>), emphasized the role of the inflammation component in the context of fibrosis and underscored the model-specific involvement of PFs in cholestatic fibrosis.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Liver cell-type dynamics and cell-type-specific integrin expression during fibrogenesis and healing.</title><p>(<bold>A–D</bold>) Box plots show mean <italic>z</italic>-scored mass spectrometry (MS) intensities of the indicated cell-type-specific protein signatures in time. Hepatocytes (A; n=18), hepatic stellate cells (HSCs), and activated portal fibroblasts (PFs) (B; n=3 and 4), Kupffer cells (C; n=6), granulocytes, and macrophages (D; n=16 and 33). One-way ANOVA with Bonferroni’s post-test; *p&lt;0.05; **p&lt;0.01; <sup>†</sup>p&lt;0.001. (<bold>E</bold>) The line plots show the time-dependent change in MS intensities of indicated selected integrins in Total (solid line) and E-fraction (broken line) proteomes in carbon tetrachloride (CCl<sub>4</sub>) and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) models; n=4–6. (<bold>F</bold>) Representative immunofluorescence images of liver sections from untreated controls (Ctrl), CCl<sub>4</sub>-, and DDC-treated mice at time points of fibrosis development (T2) and resolution (T3) immunolabeled for integrin αv (green), K19 (red), and αSMA (blue). Arrowheads, integrin αv-positive injured hepatocytes; arrows, integrin αv-positive biliary epithelial cells of reactive ductuli. CV, central vein; PV, portal vein. Boxed areas, ×2 images. Scale bar = 50 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Dynamics of liver sinusoidal endothlial cells (LSECs) and immune cells with their cell-type-specific integrin expression profiles.</title><p>(<bold>A</bold>) Box plots show mean z-scored mass spectrometry (MS) intensities of the indicated cell-type-specific protein signatures in time. LSECs (n=3), B cells (n=7), monocytes (n=12), and CD4<sup>+</sup> T-cells (n=6). (<bold>B</bold>) The line plots show the change in MS intensities of indicated selected integrins in Total (solid line) and E-fraction (broken line) proteomes in carbon tetrachloride (CCl<sub>4</sub>) and 3,5-diethoxycarbonyl-1,4-dihy- drocollidine (DDC) models; n=4–6.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Liver cell-type-specific dynamics development during fibrogenesis and healing documented by immunofluorescence microscopy corroborates the mass spectrometry (MS)-derived cell-type-specific signature dynamics.</title><p>(<bold>A, B</bold>) Representative immunofluorescence (IF) images of liver sections from untreated controls (Ctrl), carbon tetrachloride (CCl<sub>4</sub>)-, and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-treated mice at time points of fibrosis development (T1, T2) and resolution (T3, T4) immunolabeled for indicated cell-type-specific markers. (A) HNF4α (yellow; detecting changes in hepatocyte abundance), αSMA (cyan; detecting activated hepatic stellate cells [HSCs] and portal fibroblasts), and K19 (magenta; detecting cholangiocytes). (B) B-cell marker (B220, yellow) and macrophage/monocyte/Kupffer cell marker (F4/80; magenta) together with αSMA (cyan) antibody show the role of the inflammation component in the context of fibrosis development and resolution in both models. Arrowheads, B cells recruited to the sites of injury. CV, central vein; PV, portal vein. Scale bar = 50 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig4-figsupp2-v1.tif"/></fig></fig-group><p>Cellular interactions with the changing microenvironment are mediated by integrins, a heterogeneous family of cell adhesion receptors. Thus, temporal changes in cell-type-specific integrin subsets reflect the alterations in fibrotic injury-induced cell populations with the potential to predict the fibrogenicity of the ongoing disease. Our profiling revealed increased expression of integrin β1 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>), the most abundant collagen receptor, which has been reported (together with integrins α1 and α5) to correlate with the stages of human liver fibrosis (<xref ref-type="bibr" rid="bib43">Nejjari et al., 2001</xref>). Given its cell-type-specific expression prevalence, this finding likely corresponds to the expansion of HSCs, simultaneously with induced integrin β1 expression on liver sinusoidal endothelial cells (LSECs) and injured hepatocytes (<xref ref-type="bibr" rid="bib43">Nejjari et al., 2001</xref>). A rapid immune response is documented by extensive upregulation of main leukocyte integrin subunits β2 and αM (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Their differential expression kinetics between the models correlate well with cell-type-specific signatures (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Unexpectedly, fibronectin receptor integrin α5 (typically expressed on HSCs, PFs, and LSECs [<xref ref-type="bibr" rid="bib48">Olsen et al., 2012</xref>; <xref ref-type="bibr" rid="bib8">Couvelard et al., 1993</xref>]) was detected in Total DDC proteome only (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Since a boosted expression of integrin α5 has been reported in liver tumors (<xref ref-type="bibr" rid="bib34">Lai et al., 2011</xref>), this finding further supports the tumorigenic potential of biliary fibrosis.</p><p>Strong induction of TGFβ-activating integrin αv in both CCl<sub>4</sub> and DDC Total proteomes (<xref ref-type="fig" rid="fig4">Figure 4E</xref>) reflected its central role in fibrogenesis (<xref ref-type="bibr" rid="bib53">Reed et al., 2015</xref>). Strikingly, in E-fraction, integrin αv was found to increase only in the CCl<sub>4</sub> model (<xref ref-type="fig" rid="fig4">Figure 4E</xref>), suggesting its close association with ECM specifically during hepatotoxic injury. Subsequent IF analysis showed localization of antibodies to αv mostly to periportal hepatocytes and with little signal found in central hepatocytes of control livers (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). During CCl<sub>4</sub>-induced injury, αv staining was enhanced at the periphery of pericentral hepatocytes adjacent to the collagen-rich scars, reflecting ongoing liver periportalization with the injury (<xref ref-type="bibr" rid="bib18">Ghallab et al., 2019</xref>). The zonal distribution of αv was partially restored with fibrosis regression. In DDC-driven cholestasis, antibodies to αv stained strongly with reactive biliary epithelial cells (BECs), the main drivers of fibrogenesis in biliary fibrosis (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Thus, our analysis reveals stage-specific induction of integrin αv on the surface of pericentral hepatocytes that has been unrecognized to date and suggests its potential as a marker of reactive BECs in cholestasis.</p></sec><sec id="s2-5"><title>Analysis of solubility profile dynamics of liver proteome reveals extracellular matrix protein-1 among matrisome proteins induced by fibrogenesis</title><p>As ECM remodeling during fibrogenesis also entails changes in the solubility of its constituents and associated proteins (<xref ref-type="bibr" rid="bib55">Schiller et al., 2015</xref>), we next set out to identify proteins that become increasingly insoluble with fibrosis progression. We found 1273 (CCl<sub>4</sub>) and 762 (DDC) differentially expressed proteins, defined by at least threefold higher expression in E- than in S-fraction (see Materials and methods). Hierarchical clustering of their MS intensity ratios clearly reflected changes in protein solubility profiles in the course of disease progression (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A and B</xref>). Proteins grouped into three (CCl<sub>4</sub>, 406 proteins) and two (DDC, 63 proteins) ECM-enriched clusters exhibited increasing insolubility during fibrogenesis. Matrisome proteins found in both fibrotic models were mainly collagens and ECM glycoproteins (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Interestingly, we identified 93 (CCl<sub>4</sub>) and 16 (DDC) proteins not present in control samples but induced by treatment (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>). Abundance of most of the identified proteins in E-fraction decreased with healing in the CCl<sub>4</sub> but not in the DDC model (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), suggesting model-specific incorporation of matrisome-associated proteins into insoluble ECM.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Solubility profiling provides in-depth analysis of model-specific matrisome composition.</title><p>(<bold>A</bold>) Venn diagram shows relative proportion of proteins from E-fraction proteome identified as proteins with increasing insolubility over the course of fibrosis in each model (see <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A and B</xref> and Materials and methods). Matrisome proteins are highlighted with color coding to indicate identified matrisome categories. (<bold>B, C</bold>) Line plots show time-dependent change in mass spectrometry (MS) intensities of indicated selected matrisome proteins uniquely identified in E-fraction (broken line) proteomes in carbon tetrachloride (CCl<sub>4</sub>) and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) models; n=4–6. (Solid line shows MS intensity profile in Total proteome.) (<bold>C</bold>) Representative immunofluorescence images of liver sections from untreated controls (Ctrl), CCl<sub>4</sub>-, and DDC-treated mice at indicated time points of fibrosis development (T1 and T2) and resolution (T4) immunolabeled for ECM1 (green) and collagen type I (red). Nuclei were stained with DAPI (blue). Arrows, ECM1-positive reactive biliary epithelial cells. CV, central vein; PV, portal vein. Boxed areas, ×2 images. Scale bar = 50 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Analysis of matrisome proteins identified in carbon tetrachloride (CCl<sub>4</sub>)- and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-derived E-fraction proteomes.</title><p>(<bold>A, B</bold>) Unsupervised hierarchical clustering of mass spectrometry intensity ratios (E-fraction/S-fraction) of proteins differentially expressed in E-fraction in CCl<sub>4</sub> (A) and DDC (B) model. UniProtKB keyword enrichment annotations for clusters of proteins (CCl<sub>4</sub> clusters I–III in A; DDC clusters I and II in B) with decreasing solubility over the course of fibrosis are shown (extracellular matrix [ECM]-related keywords in blue). (<bold>C</bold>) Venn diagram shows a comparison of matrisome proteins detected during fibrosis development (T1 and T2) but not in control samples in E-fraction proteomes of CCl<sub>4</sub> and DDC model. Color coding indicates identified matrisome categories. (<bold>D</bold>) Representative immunofluorescence images of liver sections from untreated controls (Ctrl) immunolabeled for ECM1 (green) and desmin (red; upper panel) or F4/80 (red; lower panel). Nuclei were stained with DAPI (blue). Note the colocalization of ECM1 with F4/80 positive cells (in yellow; lower panel). PV, portal vein. Scale bar = 50 μm. (<bold>E</bold>) Bar graph shows the quantification of percentage of ECM1<sup>+</sup> area per field of view (using ×40 objective) within the injury affected area (CV area in CCl<sub>4</sub> model and PV area in DDC model) at selected time points.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig5-figsupp1-v1.tif"/></fig></fig-group><p>Among proteins upregulated with disease onset in E-fractions of both fibrotic models was extracellular matrix protein-1 (ECM1; <xref ref-type="fig" rid="fig5">Figure 5C</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>). Subsequent IF analysis confirmed weak ECM1 staining (corresponding to low expression levels) in control livers, which was confined mostly to Kupffer cells and the apical membrane of BECs (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). Increased ECM1 abundance during fibrogenesis was paralleled by its increasing localization within the infiltrating inflammatory cells and activated Kupffer cells. In addition, ECM1 heavily decorated apical membranes of BECs forming reactive ductuli in DDC-treated livers, thus corresponding to higher MS intensity of ECM1 during the development of biliary fibrosis. Quantification of IF staining also showed dynamic changes in ECM1 antigen abundance during fibrosis development and resolution thus confirming the MS data (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>). Induction of ECM1 expression in the inflammatory cells at the sites of primary injury in the CCl<sub>4</sub> model and in reactive ductuli in the DDC model strongly indicates its involvement in fibrogenesis and healing. Although a previous study had identified ECM1 expression to be hepatocyte-specific (<xref ref-type="bibr" rid="bib14">Fan et al., 2019</xref>), our data suggest that its role might be more complex than anticipated.</p></sec><sec id="s2-6"><title>Correlation of dynamic changes of hepatotoxic proteome and fibrotic deposits identifies clusterin as a novel protein associated with fibrosis resolution</title><p>The CCl<sub>4</sub> model gradually developed typical bridging liver fibrosis (<xref ref-type="bibr" rid="bib35">Liu et al., 2013</xref>) followed by fibrosis resolution as documented by liver injury markers (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>) and collagen deposits (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>), as well as by results of our MS profiling (<xref ref-type="fig" rid="fig2">Figure 2</xref>). These dynamic changes allowed us to correlate protein abundance profiles (from both Total and E-fraction proteomes) with disease dynamics (captured as fibrotic area) in individual mice (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). For example, leukocyte-specific integrin β2-interacting protein coronin 1a (CORO1A) displayed a significant positive correlation with fibrogenesis reflecting the time course of the immune response (<xref ref-type="fig" rid="fig6">Figure 6B and C</xref>). In contrast, negatively correlating methionine cycle enzyme adenosylhomocysteinase (AHCY) corresponded to hepatocellular death induced by fibrogenesis (<xref ref-type="fig" rid="fig6">Figure 6B and C</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Correlation analysis of protein abundance and changes in fibrotic deposits in the hepatotoxic model associates clusterin with fibrosis resolution.</title><p>(<bold>A</bold>) Schematic illustrates the correlation of protein abundance changes with changes in sirius red-positive (SR<sup>+</sup>) areas of fibrous extracellular matrix (ECM) deposits in carbon tetrachloride (CCl<sub>4</sub>)-treated animals at the indicated time points. (<bold>B</bold>) The regulator of the actin cytoskeleton, coronin 1a (CORO1A), serves as an example of a protein with a positive slope of the correlation fit. The methionine cycle enzyme, adenosylhomocysteinase (AHCY), serves as an example of a protein with a negative slope of the correlation fit. (<bold>C, D</bold>) The scatter plots show the linear regression slope and the Pearson correlation coefficient for proteins of CCl<sub>4</sub> Total (C), and E-fraction (D) proteomes. Statistical significance of the correlation is color-coded as indicated. The line plots show time-dependent change in mass spectrometry (MS) intensities of indicated representative proteins with significant correlation in Total (solid line) and E-fraction (broken line) proteomes in CCl<sub>4</sub> and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) models; n=4–6. (<bold>E</bold>) Representative immunofluorescence (IF) images of liver sections from untreated controls (Ctrl), CCl<sub>4</sub>-, and DDC-treated mice at indicated time points of fibrosis development (T2) and resolution (T3 and T4) immunolabeled for clusterin (Clu, green), keratin 19 (K19, red), and collagen type I (Col1, blue). Arrowheads, clusterin staining signal delineating collagen deposits; arrows, clusterin-positive injured hepatocytes; yellow arrows, clusterin-positive biliary epithelial cells. CV, central vein; PV, portal vein. Boxed areas, ×2 images. Scale bar = 50 μm. (<bold>F</bold>) Representative IF images of human liver sections from different stages of chronic liver diseases of various etiologies (biliary-type, steatotic liver disease, and chronic hepatitis C [HCV] infection) immunolabeled for clusterin (Clu, green) and collagen type I (Col1, magenta). Nuclei were stained with DAPI (blue). Top row shows increase in clusterin expression along collagen fibrils in biliary-type and metabolic syndrome-related cirrhosis compared to the stage of mild fibrosis. Bottom row documents change in clusterin staining pattern with chronic HCV progression from fibrosis stage F1 to stage F4 (METAVIR grading system: F1, portal fibrosis; F2, periportal fibrosis; F3, bridging septal fibrosis; F4, cirrhosis). Arrowheads, clusterin staining delineating collagen deposits; arrows, clusterin-positive capillarized sinusoids; yellow arrows, clusterin-positive bile canaliculi (stage F1 only). PV, portal vein. Boxed areas, ×4 images. Scale bar = 50 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Ingenuity Pathway Analysis (IPA) canonical signaling pathways predicted from correlation analysis.</title><p>(<bold>A, B</bold>) Canonical signaling pathways identified (IPA) for proteins with significant correlation with fibrous extracellular matrix (ECM) deposits from carbon tetrachloride (CCl<sub>4</sub>)-derived Total (A) and E-fraction (B) proteomes.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Clusterin expression in control and diseased human livers.</title><p>(<bold>A</bold>) Representative immunofluorescence (IF) image of control human liver sections immunolabeled for clusterin (green) and collagen type I (Col1, magenta). Nuclei were stained with DAPI (blue). Note no clusterin expression in healthy parenchyma. Scale bar = 50 μm. (<bold>B</bold>) Representative IF images of human liver sections from different stages of chronic hepatitis C (HCV) infection immunolabeled for clusterin (green) and collagen type I (Col1, magenta). Nuclei were stained with DAPI (blue). The images document change in clusterin staining pattern with fibrosis progression from stage F1 to stage F4 according the METAVIR grading system (F1, portal fibrosis; F2, periportal fibrosis; F3, bridging septal fibrosis; F4, cirrhosis). Note clusterin-positive bile canaliculi in stage F1 (yellow arrows); clusterin-positive granuli associated with sinusoids in F2 (arrow); clusterin positive collagen fibers within sinusoids in F3 (arrowhead); clusterin-positive collagen fibers within parenchyma in F4 (arrowheads). Scale bar = 25 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig6-figsupp2-v1.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>Correlation analysis of protein abundance and changes in fibrotic deposits in the cholestatic model.</title><p>The scatter plots show the linear regression slope and the Pearson correlation coefficient for proteins of 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) Total (left panel), and E-fraction (right panel) proteomes. The statistical significance of the correlation is color-coded as indicated.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig6-figsupp3-v1.tif"/></fig></fig-group><p>In the Total CCl<sub>4</sub> proteome, proteins positively correlating with fibrogenesis included matrisome proteins (e.g. angiotensinogen, fibrinogen α,β,γ-chains, fibrinogen-like protein 1, and fibronectin). The IPA linked these to the inflammation and pathways associated with ECM-cell interactions, such as ‘actin cytoskeleton signaling’ and ‘integrin signaling’ (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). Proteins with negative correlation were mostly enzymes involved in hepatocyte metabolism, such as alpha-enolase (ENO1), an enzyme shown to participate as plasminogen receptor in ECM degradation (<xref ref-type="bibr" rid="bib11">Didiasova et al., 2019</xref>). Analogously to Total proteome, proteins of CCl<sub>4</sub> E-fraction positively correlating with fibrosis area were linked to fibrogenesis (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Displaying negative correlation was a group of 41 proteins consisting mainly of enzymes associated with amino acid metabolism, necrosis, and apoptosis (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). In addition, three core matrisome proteins – decorin, microfibrillar-associated protein 2 (MFAP2), and collagen type I α-1 chain – were also identified. As shown for collagen type I α-1 chain, their MS intensity temporal profiles indicated their upregulation in E-fraction while their overall abundance decreased with healing (<xref ref-type="fig" rid="fig6">Figure 6D</xref>), likely corresponding to the increased association of these matrisome proteins with degraded insoluble ECM.</p><p>Among proteins positively correlating with fibrotic scar development and resolution in both Total and insoluble proteomes was clusterin (CLU), a glycoprotein implicated in several diseases (<xref ref-type="fig" rid="fig6">Figure 6D</xref>; <xref ref-type="bibr" rid="bib65">Wilson and Zoubeidi, 2017</xref>). As clusterin imparts extracellular chaperone function not previously linked to fibrosis, we next investigated clusterin’s localization by IF microscopy (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). In untreated livers, clusterin was detected in BECs and partially in hepatocytes. Upon CCl<sub>4</sub> intoxication, IF staining revealed its prominent expression by damaged hepatocytes. Strikingly, clusterin increasingly re-localized along the collagen deposits over the healing period. In DDC-treated livers, clusterin was found mostly in BECs forming reactive ductuli and in hepatocytes, with minimal changes upon healing (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). Moreover, extracellular clusterin deposition in close proximity of collagen fibers was further demonstrated in fibrotic and cirrhotic human livers of various etiologies at different stages of fibrosis (<xref ref-type="fig" rid="fig6">Figure 6F</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>). The gradual increase in clusterin expression with the progression of fibrosis against the background of chronic hepatitis C (METAVIR score F1-F4) further emphasized its role in the development of liver fibrotic diseases.</p></sec><sec id="s2-7"><title>Interface hepatocyte elasticity responds dynamically to the pericentral injury in the course of fibrosis development</title><p>Identification of ‘Rho-A’, ‘Rho family GTPases’, ‘actin cytoskeleton’, and ‘integrin/ILK signaling’ among top canonical pathways elicited by proteins of Total CCl<sub>4</sub> proteome together with the proteins of matrisome-enriched clusters (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A and C</xref>) suggested that the hepatotoxic injury leads to increased cytoskeletal tension in injured hepatocytes. This was further supported by significant enrichment in intermediate filament proteins (<xref ref-type="fig" rid="fig2">Figure 2E</xref>) and in MRTF targets (e.g. ITGA1, THBS1, ACTR2, and MSN; <xref ref-type="fig" rid="fig7">Figure 7A</xref>), key regulators involved in cell and tissue mechanics, cytoskeletal dynamics, and mechanosensing (<xref ref-type="bibr" rid="bib13">Esnault et al., 2014</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Atomic force microscopy (AFM) stiffness mapping reveals changes in the local mechanics of liver tissue upon hepatotoxic injury.</title><p>(<bold>A</bold>) The line plot shows the dynamics of 32 myocardin-related transcription factor (MRTF) targets (highlighted in black) significantly enriched in extracellular matrix (ECM)-enriched cluster I of carbon tetrachloride (CCl<sub>4</sub>) Total proteome (<xref ref-type="fig" rid="fig2">Figure 2C</xref>) identified by Fisher’s exact test (p=0.01; Benjamini-Hochberg false discovery rate = 3%). (<bold>B, C</bold>) Representative polarized microscopy images of CCl<sub>4</sub>-treated (T2, B) and untreated control (Ctrl, C) liver sections with indicated regions (1–3) selected for AFM measurements. Note in (B) white areas corresponding to collagen fibers visualized by polarized light. Pink rectangle, region 1 (collagen-rich fiber); green rectangle, region 2 (injured hepatocytes); yellow rectangle, region 3 (interface hepatocytes). CV, central vein; PV, portal vein. Scale bar = 100 μm. Histogram shows Young’s moduli for the measured regions in untreated control livers; n=7 regions in three mice. (<bold>D–F</bold>) Representative polarized microscopy images of CCl<sub>4</sub>-treated (T2) liver sections with rectangle indicating the regions of AFM measurements (30×100 μm<sup>2</sup>) and corresponding pseudocolor Young’s modulus maps determined by AFM. Scale bar = 25 μm. Histograms show Young’s moduli for indicated regions of collagen-rich fibers (D), injured hepatocytes (E), and interface hepatocytes (F) at indicated time points of fibrosis development (T1 and T2) and spontaneous resolution (T4). Inset scatter plots show Young’s modulus values above 10 kPa for each time point; n=7 regions in three mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Correlation analysis of protein abundance change and changes in mechanical properties of the local mechanics of liver tissue upon hepatotoxic injury.</title><p>(<bold>A, B</bold>) The scatter plots show the linear regression slope and the Pearson correlation coefficient for proteins of carbon tetrachloride (CCl<sub>4</sub>) Total proteome (A) and CCl<sub>4</sub> E-fraction proteome (B) with average Young’s moduli of collagen-rich areas, injured hepatocyte areas, and interface hepatocyte areas. The statistical significance of the correlation is color-coded as indicated.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-fig7-figsupp1-v1.tif"/></fig></fig-group><p>As variations in ECM composition and content also substantially affect the biomechanics of liver tissue, we decided to examine correlation between our proteomic results and mapping of dynamic changes in the biomechanical properties of CCl<sub>4</sub>-treated livers. We used atomic force microscopy (AFM) combined with polarized microscopy (<xref ref-type="bibr" rid="bib46">Ojha et al., 2022</xref>) to precisely locate and probe the following compartments: (1) regions of collagen-rich scar tissue in close vicinity of the central vein, (2) injured hepatocyte regions next to the collagen scar, and (3) regions of hepatocytes on the interface between injured and not visibly damaged hepatocytes (so-called interface hepatocytes; <xref ref-type="bibr" rid="bib6">Ben-Moshe et al., 2022</xref>; <xref ref-type="fig" rid="fig7">Figure 7B</xref>). In parallel, we also measured stiffness of corresponding regions in nontreated control liver sections (<xref ref-type="fig" rid="fig7">Figure 7C</xref>).</p><p>Our AFM analysis revealed no substantial topological variations across defined compartments in control livers, with median Young’s moduli ranging between 1.2 and 1.6 kPa (<xref ref-type="fig" rid="fig7">Figure 7C</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). Fibrogenic response triggered progressive tissue stiffening apparent in all analyzed compartments (<xref ref-type="fig" rid="fig7">Figure 7D–F</xref>, <xref ref-type="table" rid="table1">Table 1</xref>), with collagen-rich regions the stiffest at maximal fibrosis (~4.4 kPa at T2; <xref ref-type="fig" rid="fig7">Figure 7D</xref>). Unexpectedly, interface regions exhibited initial softening (T1; median ~0.8 kPa vs. 1.2 kPa in control livers), which was followed by increase in stiffness up to ~2.0 kPa (T2). With healing (T4), all compartments demonstrated clear decrease in stiffness (<xref ref-type="fig" rid="fig7">Figure 7D–F</xref>), although this was only marginal in the regions corresponding to injured hepatocytes. Significant softening of collagen-rich scar tissue during healing indicated partial resolution of scar-associated ECM while it associated with the incorporation of several core matrisome proteins (e.g. COL1A1 and FBN1) into the scar tissue (<xref ref-type="fig" rid="fig1">Figures 1F</xref> and <xref ref-type="fig" rid="fig6">6D</xref>). Although the heterogeneity of AFM-based measurements constituted a limitation on our correlation analysis relative to proteomic data (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>), this analysis provides a coherent framework for better understanding the dynamics of proteomic landscapes in the context of fibrosis-associated changes in the local mechanics of liver tissue.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Median Young’s moduli for each defined area and treatment.</title><p>Statistical analysis was performed on frequency distribution data using Kruskal-Wallis test followed by Dunn’s multiple comparison post-testing. *p&lt;0.05, **p&lt;0.01 vs. control.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top"/><th align="left" valign="top" colspan="3">Median Young’s modulus (kPa)</th></tr></thead><tbody><tr><td align="left" valign="top">Treatment</td><td align="left" valign="top">Collagen area</td><td align="left" valign="top">Affected hepatocyte area</td><td align="left" valign="top">Interface hepatocyte area</td></tr><tr><td align="left" valign="top">Control (substitute area)</td><td align="char" char="." valign="top">1.6</td><td align="char" char="." valign="top">1.3</td><td align="char" char="." valign="top">1.2</td></tr><tr><td align="char" char="." valign="top">3 week CCl<sub>4</sub> (T1)</td><td align="char" char="." valign="top">2.7**</td><td align="char" char="." valign="top">1.9**</td><td align="char" char="." valign="top">0.8**</td></tr><tr><td align="char" char="." valign="top">6 week CCl<sub>4</sub> (T2)</td><td align="char" char="." valign="top">4.4**</td><td align="char" char="." valign="top">2.8**</td><td align="char" char="." valign="top">2.0*</td></tr><tr><td align="char" char="." valign="top">6 weeks+10 days (T4)</td><td align="char" char="." valign="top">3.0</td><td align="char" char="." valign="top">2.5*</td><td align="char" char="." valign="top">1.4</td></tr></tbody></table></table-wrap></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we comprehensively characterized and compared dynamic proteomic landscapes of liver fibrosis development and repair in two mouse models based either on repetitive CCl<sub>4</sub> intoxication (<xref ref-type="bibr" rid="bib35">Liu et al., 2013</xref>) or on DDC feeding (<xref ref-type="bibr" rid="bib15">Fickert et al., 2007</xref>). These models are widely used to reliably mimic either hepatotoxic (CCl<sub>4</sub>) or cholestatic (DDC) liver injuries leading to fibrosis in humans (<xref ref-type="bibr" rid="bib35">Liu et al., 2013</xref>). Previous attempts to grasp the complexity of etiology-specific fibrotic proteomes with a focus on diseased ECM (<xref ref-type="bibr" rid="bib38">Massey et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Klaas et al., 2016</xref>) were limited due to origins of the analyzed material (mostly decellularized samples) and yielded only fragmented insight into the time course of the disease. To fill this research gap, we employed detergent-based tissue extraction and analyzed both Total and insoluble fraction proteomes at multiple time points of disease progression and spontaneous healing. This approach allowed us to (1) compare time-resolved, compartment-specific proteomes of CCl<sub>4</sub> and DDC models, (2) define etiology-specific elements of fibrogenesis, and (3) detect even low-abundance matrisome and matrisome-interacting proteins in the ECM-enriched insoluble fraction samples. Further, our detailed AFM-based profiling of CCl<sub>4</sub>-treated livers enabled us to relate our proteomic data to disease-associated changes in the local mechanics of liver tissue.</p><p>We and others have demonstrated that the nature of liver injury determines the set of components assembled in diseased ECM (<xref ref-type="bibr" rid="bib31">Klaas et al., 2016</xref>), which thus reflects unique features of the injury. For instance, the initial decline in abundance of hepatocyte- and activated BEC-expressed collagen type XVIII α-1 chain (<xref ref-type="bibr" rid="bib56">Schuppan et al., 1998</xref>) and its consecutive increase thereafter in the hepatotoxic CCl<sub>4</sub> model corresponds to hepatocyte death followed by expansion of both collagen type XVIII α-1 chain-expressing cell types (<xref ref-type="bibr" rid="bib37">Manco et al., 2019</xref>). By contrast, extensive collagen type XVIII α-1 chain expression in DDC-induced cholestasis was already apparent in the early fibrotic deposits due to a massive ductular reaction. A prominent group of BM-associated proteins uniquely identified in the cholestatic model can be attributed to activated BECs in proliferating bile ducts. Some of them (e.g. collagen type XVIII α-1 chain, collagen type IV and VI α-2 chains, and perlecan) are among the 14-gene signature potently predicting human patient cirrhosis progression and survival (<xref ref-type="bibr" rid="bib66">Wu et al., 2021</xref>). Other DDC matrisome constituents (e.g. collagen type III α-1 chain, elastin, and laminin subunit gamma 1) have been recently linked to the deterioration of hepatocyte functions in connection with ECM stiffening (<xref ref-type="bibr" rid="bib1">Acun et al., 2021</xref>). Notably, elastin is present in liver biopsies from patients with advanced fibrosis and adverse clinical outcome (<xref ref-type="bibr" rid="bib29">Kendall et al., 2018</xref>) and is associated with the irreversibility of liver fibrosis. Further, the increased incorporation of cross-linking protein LOXL1 and TGFβ1-related protein LTBP4 into DDC-specific ECM underscores its resemblance to human cirrhotic liver ECM (<xref ref-type="bibr" rid="bib39">Mazza et al., 2019</xref>). Hence, our findings indicate that cholestasis-driven ECM deposits contain numerous proteins detected in more advanced stages of liver disease favoring hepatocarcinogenesis with a compromised ability to heal. Moreover, identified cholestasis-induced unique signaling pathways were analogous to those recently identified in a subtype of mouse cancer models mimicking human cholangiocarcinoma-like hepatocellular cancer (<xref ref-type="bibr" rid="bib61">Tang et al., 2022</xref>).</p><p>Our observations are concordant with recently published studies (reviewed in <xref ref-type="bibr" rid="bib30">Kisseleva and Brenner, 2021</xref>) revealing that in the fibrotic liver resident and nonresident cell types wire into dynamic intercellular hubs with shifting cell populations, reflecting and shaping the disease course in an etiology-specific manner. Many of the feedback mechanisms between the cells and ECM regulating fibrosis are mediated by members of the integrin family. In agreement with previous studies (<xref ref-type="bibr" rid="bib43">Nejjari et al., 2001</xref>), we observed in both models significant upregulation of all detected integrin subunits during fibrosis progression. Strong induction of integrin αM expression in cholestatic but not hepatotoxic injury documents the role of leukocyte-specific integrin αMβ2 in the modulation of biliary fibrosis (<xref ref-type="bibr" rid="bib27">Joshi et al., 2016</xref>), suggesting that the integrin αM might thus serve as a possible selective target for treatment of cholestatic liver disease. Further, a prominent transition of TGFβ1-activating integrin αv toward insoluble ECM exclusively upon hepatotoxic injury was accompanied by its localization to injured pericentral hepatocytes near collagen-rich scars and αSMA-positive HSCs. This finding, together with a measured increase in the stiffness of injured hepatocytes, implies an active role of integrin αv in the targeted activation of TGFβ1 in the local microenvironment during centrilobular fibrosis. Indeed, integrin αv located on hepatocytes in the vicinity of biliary fibrotic septa has been suggested to indicate hepatocyte biliary transformation (<xref ref-type="bibr" rid="bib50">Popov et al., 2008</xref>). Here, we propose that compartment-specific induction of αv expression on the surface of scar-associated hepatocytes could be a general mechanism to promote fibrosis progression.</p><p>In contrast to the cholestatic DDC model, hepatotoxic injury in the CCl<sub>4</sub> model showed a substantial ability to heal 10 days after challenge withdrawal. Such healing capacity allowed us to correlate the dynamics in CCl<sub>4</sub> proteomes with the changes in fibrotic deposits not only during fibrosis progression but also in resolution. Among proteins correlating with scar tissue formation in both Total and insoluble proteomes, we identified a small molecular chaperone clusterin. Clusterin is believed to be associated with elastin fibers in cholestasis (<xref ref-type="bibr" rid="bib2">Aigelsreiter et al., 2009</xref>), and recently it was linked to the attenuation of mouse hepatic fibrosis (<xref ref-type="bibr" rid="bib57">Seo et al., 2019</xref>). Here, we localized clusterin exclusively to injured, pathologically stiffer hepatocytes. Interestingly, the clusterin promoter comprises binding motifs for mechanosensitive transcription factors such as c-Fos and AP-1/Jun (<xref ref-type="bibr" rid="bib25">Jin and Howe, 1999</xref>; <xref ref-type="bibr" rid="bib41">Miyamoto-Sato et al., 2010</xref>). This suggests that local clusterin induction can reflect the dynamic changes of microenvironmental mechanical cues. Most intriguingly, we also found clusterin to associate with collagen-rich ECM deposits in the course of mouse fibrosis regression and with pathological human matrix of various etiologies. As clusterin overexpression associates with increased activity of ECM-degrading matrix metalloproteinases (<xref ref-type="bibr" rid="bib59">Shim et al., 2011</xref>), we hypothesize that clusterin accumulation facilitates the remodeling and resolution of scar tissue. Although the specific molecular function of clusterin in fibrotic tissue repair processes remains to be determined, our results strongly suggest clusterin to be an attractive antifibrotic target.</p><p>Liver cell and tissue mechanics play a pivotal role in the processes that initiate and resolve fibrotic injury (<xref ref-type="bibr" rid="bib20">Henderson et al., 2020</xref>). Initial disruption of mechanical homeostasis prompts cytoskeletal remodeling that alters cell-generated forces and cellular biomechanics. Here, such a shift to a higher stiffness regime is illustrated by prominent changes in cytoskeleton-related signatures (actin and intermediate filaments) and signatures of mechanosensitive transcription regulators (e.g., MRTF) accompanied by a significant stiffening of parenchymal compartments devoid of apparent collagen deposits. This indicates substantial cell-driven changes in the biomechanical properties of tissue microenvironment. An unexpected decrease in the stiffness of interface hepatocytes with the initial fibrotic changes revealed by our AFM analysis suggests that the initial softening of interface hepatocytes upon injury counterbalances the stiffening of the injured hepatocytes and/or fibrous scar tissue regions. As the interface hepatocytes have been shown to undergo a phenotypic shift in response to the injury (<xref ref-type="bibr" rid="bib6">Ben-Moshe et al., 2022</xref>), it will now be interesting to determine whether altered mechanical properties serve as the cue leading to the genetic fetal reprogramming or if this initial softening is due to the expression of fetal markers. Together, our AFM and proteomic data underscore the role of local tissue stiffening in fibrotic response and postulate involvement of tissue softening during resolution not only in the collagen scar tissue but also in regenerating parenchyma.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti- K19 (TROMA III; Rat monoclonal)</td><td align="left" valign="bottom">DSHB</td><td align="left" valign="bottom">TROMA III<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2133570">AB_2133570</ext-link></td><td align="left" valign="bottom">IHCP (1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-αSMA (1A4; Mouse monoclonal)</td><td align="left" valign="bottom">DAKO</td><td align="left" valign="bottom">M0851<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2223500">AB_2223500</ext-link></td><td align="left" valign="bottom">IHCP (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-ECM1 (F-1; Mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">sc-365335<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_10847810">AB_10847810</ext-link></td><td align="left" valign="bottom">IHCP (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-clusterin (goat polyclonal)</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">AF2747<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2083314">AB_2083314</ext-link></td><td align="left" valign="bottom">IHCP (1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-clusterin (A-11; Mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">sc-166831<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2245186">AB_2245186</ext-link></td><td align="left" valign="bottom">IHCP (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-fibronectin (Rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab2413<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2262874">AB_2262874</ext-link></td><td align="left" valign="bottom">IHCP (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-collagen I (Rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab21286<break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_446161">AB_446161</ext-link></td><td align="left" valign="bottom">IHCP (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-collagen IV (Rabbit polyclonal)</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">2150-1470</td><td align="left" valign="bottom">IHCP (1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-integrin αV(EPR16800, mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom"/><td align="left" valign="bottom">IHCP (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-B220 (RA3-6B2, mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">103203</td><td align="left" valign="bottom">IHCP (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-F4/80(D2S9R mouse monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">70076 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2799771">AB_2799771</ext-link></td><td align="left" valign="bottom">IHCP (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-desmin (rabbit polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">PA5-16705 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_10977258">AB_10977258</ext-link></td><td align="left" valign="bottom">IHCP (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rhodamine Red-X (RRX) AffiniPure Donkey Anti-Mouse IgG (H+L)</td><td align="left" valign="bottom">Jackson ImmunoResearch</td><td align="left" valign="bottom">715-295-151 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2340832">AB_2340832</ext-link></td><td align="left" valign="bottom">IHCP (1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 488 AffiniPure F(ab')₂ Fragment Donkey Anti-Goat IgG (H+L)</td><td align="left" valign="bottom">Jackson ImmunoResearch</td><td align="left" valign="bottom">705-546-147 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2340430">AB_2340430</ext-link></td><td align="left" valign="bottom">IHCP (1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 594 AffiniPure F(ab')₂ Fragment Donkey Anti-Rat IgG (H+L)</td><td align="left" valign="bottom">Jackson ImmunoResearch</td><td align="left" valign="bottom">712-586-150 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2340690">AB_2340690</ext-link></td><td align="left" valign="bottom">IHCP (1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 647 AffiniPure Donkey Anti-Rabbit IgG (H+L)</td><td align="left" valign="bottom">Jackson ImmunoResearch</td><td align="left" valign="bottom">711-605-152 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2492288">AB_2492288</ext-link></td><td align="left" valign="bottom">IHCP (1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 488 AffiniPure Donkey Anti-Mouse IgG (H+L)</td><td align="left" valign="bottom">Jackson ImmunoResearch</td><td align="left" valign="bottom">715-545-150 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2340846">AB_2340846</ext-link></td><td align="left" valign="bottom">IHCP (1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 488 AffiniPure Donkey Anti-Rabbit IgG (H+L)</td><td align="left" valign="bottom">Jackson ImmunoResearch</td><td align="left" valign="bottom">711-545-152 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2313584">AB_2313584</ext-link></td><td align="left" valign="bottom">IHCP (1:250)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">CCl4</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">SML1656</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">SPSS</td><td align="left" valign="bottom">SPSS</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_002865">SCR_002865</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">DAPI stain</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">D1306</td><td align="left" valign="bottom">(1 µg/ml)</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">Perseus</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://maxquant.net/perseus/">https://maxquant.net/perseus/</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Version 1.6.10.43</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Ethical statement</title><sec id="s4-1-1"><title>Human samples</title><p>The use of completely anonymized archived liver tissue samples for research purposes has been approved by the Ethical Committee of the Institute of Experimental and Clinical Medicine and Thomayer University Hospital, Prague, Czech Republic. Written informed consent was obtained from all patients enrolled in the study. All research was conducted in accordance with both the Declarations of Helsinki and Istanbul.</p></sec><sec id="s4-1-2"><title>Animals</title><p>Male C57BL/6J mice (8–10 weeks of age) were housed under standard pathogen-free conditions with free access to regular chow and drinking water and a 12-hr-dark/12-hr-light cycle. All animal experiments were performed in accordance with an animal protocol approved by the Animal Care Committee of The Institute of Molecular Genetics, Prague, Czech Republic and according to EU Directive 2010/63/EU for animal experiments.</p></sec><sec id="s4-1-3"><title>Liver injury models</title><p>To induce fibrogenesis, mice were either injected intraperitoneally with 1 μl/g CCl<sub>4</sub> (diluted 1:3 with olive oil) twice a week for 3 or 6 weeks or fed a diet supplemented with 0.1% DDC (Sniff, Soest, Germany) for 2 or 4 weeks. To study fibrosis resolution, mice treated with CCl<sub>4</sub> for 6 weeks or fed DDC for 4 weeks were removed from treatment and allowed to recover for 5–10 days. At the end of treatment, mice were anesthetized, blood was collected into heparin-containing tubes (KabeLabortechnik, Numbrecht, Germany) to obtain plasma, and mice were sacrificed by cervical dislocation to collect liver samples. Plasma levels of aspartate transaminase, alanine transaminase, alkaline phosphatase, and total bilirubin were measured using commercial kits (Roche Diagnostics, Prague, Czech Republic).</p><p>A 1-mm-thick middle section of left lateral liver lobe was removed and two ~1 mm<sup>3</sup> pieces were cut, flash-frozen in liquid nitrogen, and stored at –80°C for further processing for mass spectrometry (MS). The rest of the lobe was divided into two parts: one was fixed in 4% buffered formalin (pH 7.4) followed by paraffin embedding for histology and immunostaining and the other was embedded in OCT Tissue-Tek (Sakura Finetek, USA) for further cryosectioning for AFM measurements.</p></sec></sec><sec id="s4-2"><title>Histology and IF</title><p>Formalin-fixed, paraffin-embedded liver sections (4 µm; both mouse and human) were stained with hematoxylin and eosin and sirius red. For IF, these sections were de-paraffinized and subjected to heat-induced antigen retrieval in Tris-EDTA (pH 9) or citrate (pH 6) buffer and further permeabilized with 0.1 M glycine, 0.1% Triton X-100 (15 min). Next, sections were incubated with primary antibodies overnight at 4°C, followed by incubation with secondary antibodies for 120 min at 22°C. The following primary antibodies were used: rat mAb to K19 (Troma III; Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA, USA); mouse mAbs to αSMA (DAKO, Glostrup, Denmark) and ECM1 (Santa Cruz Biotechnology, Dallas, TX, USA), goat polyclonal antibodies to clusterin (R&amp;D Systems, Minneapolis, MN, USA), rabbit polyclonal antibodies to fibronectin, collagen type I, collagen type IV, and monoclonal to integrin αV (all from Abcam, Cambridge, UK). As secondary antibodies we used donkey anti-mouse IgG Alexa Fluor (AF) 488 and 647, goat anti-mouse IgG and goat anti-rabbit IgG horseradish peroxidase-conjugated, donkey anti-rabbit IgG AF488, donkey anti-rat IgG AF594 (all from Jackson ImmunoResearch, Baltimore, MD, USA). ECM1 and integrin αV were visualized using Alexa Fluor 488 Tyramide Reagent (Thermo Fisher Scientific, Prague, Czech Republic) according to the manufacturer’s instructions. Stained sections were further mounted with ProLongGold Antifade mounting media (Thermo Fisher Scientific) and images were acquired with inverted fluorescence microscope DM6000 (Leica Microsystems, Pragolab, Prague, Czech Republic) equipped with HC PL Apo ×10/0.40 NA, PH1 HC PLAN Apo ×20/0.70 NA, and PH2 HCX PL Apo ×40/0.75 NA, objective lenses.</p></sec><sec id="s4-3"><title>MS sample preparation</title><p>A sample of ca 1 mm<sup>3</sup> excised from the middle section of left lateral liver lobe was cryo-homogenized using TissueLyser II (QIAGEN, Germantown, MD, USA). The cryo-homogenized liver powder was then resuspended in 200 µl of 50 mM Tris-HCl pH 7.5, 5% glycerol, 500 mM NaCl, 1% IGEPAL CA-630, 2% sodium deoxycholate, 1% SDS, 1× Proteinase Inhibitor Cocktail. The suspension was sonicated after 20 min incubation at 22°C. A 50 μl aliquot of the resuspended sample was further precipitated with ice-cold acetone and labeled ‘Total’. The remaining solution was centrifuged at 16,000 × <italic>g</italic> for 20 min to separate the supernatant containing soluble (S)-fraction from the pellet, which itself contained insoluble ECM-enriched (E)-fraction. Supernatants were further precipitated with ice-cold acetone and stored together with pellets at –80°C for further processing preceding MS analysis.</p></sec><sec id="s4-4"><title>Protein digestion</title><p>Protein pellets were homogenized and lysed in 100 mM triethylammonium bicarbonate (TEAB) containing 2% sodium deoxycholate, 40 mM chloroacetamide, 10 mM Tris(2-carboxyethyl)phosphine at 95°C for 10 min followed by sonication (Bandelin Sonopuls Mini 20 homogenizer). Protein concentration was determined using a BCA protein assay kit (Thermo Fisher Scientific) and 30 µg of protein per sample was used for MS sample preparation as described before (<xref ref-type="bibr" rid="bib22">Hughes et al., 2019</xref>). Briefly, 5 µl of SP3 beads were added to 30 µg of protein sample and brought to 50 µl with 100 mM TEAB. Protein binding was induced by the addition of ethanol to 60% (vol/vol) final concentration. Samples were mixed and incubated for 5 min at 22°C. After binding, tubes were placed into the magnetic rack and the unbound supernatant was discarded. Beads were subsequently washed two times with 180 µl of 80% ethanol. Samples were further digested with trypsin (trypsin/protein ratio 1/30, reconstituted in 100 mM TEAB) at 37°C overnight followed by acidification with trifluoroacetic acid to 1% final concentration. Peptides were desalted using in-house-made stage tips packed with 3M Empore C8 extraction disks (Thermo Fisher Scientific) as described before (<xref ref-type="bibr" rid="bib52">Rappsilber et al., 2007</xref>).</p></sec><sec id="s4-5"><title>nLC-MS/MS analysis</title><p>Nano Reversed phase columns (EASY-Spray column, 50 cm × 75 µm ID, PepMap C18, 2 µm particles, 100 Å pore size) were used for LC/MS analysis using 0.1% formic acid in water as mobile phase buffer A and 0.1% formic acid in acetonitrile as mobile phase B. Samples were loaded onto the trap column (C18 PepMap100, 5 μm particle size, 300 μm × 5 mm; Thermo Fisher Scientific) for 4 min at 18 μl/min in loading buffer (2% acetonitrile, 0.1% trifluoroacetic acid). Peptides were eluted with mobile phase B gradient from 4% to 35% in 120 min. Eluting peptide cations were converted to gas-phase ions by electrospray ionization and analyzed on a Thermo Orbitrap Fusion (Q-OT-qIT, Thermo Scientific). Survey scans of peptide precursors from 350 to 1400 m/z were performed in orbitrap at 120 K resolution (at 200 m/z) with a 5 × 10<sup>5</sup> ion count target. Tandem MS was performed by isolation at 1.5 Th with the quadrupole, HCD fragmentation with a normalized collision energy of 30, and rapid scan MS analysis in the ion trap. The MS2 ion count target was set to 10<sup>4</sup> with the max injection time of 35 ms. Only those precursors with charge state 2–6 were sampled for MS2. The dynamic exclusion duration was set to 45 s with a 10 ppm tolerance around the selected precursor and its isotopes. Monoisotopic precursor selection was turned on. The instrument was run in top speed mode with 2 s cycles (<xref ref-type="bibr" rid="bib19">Hebert et al., 2014</xref>).</p></sec><sec id="s4-6"><title>MS intensity data quantification</title><p>Peptides were identified and quantified by MaxQuant label-free quantification software (1.6.7 version; <xref ref-type="bibr" rid="bib9">Cox and Mann, 2008</xref>) using <italic>Mus musculus</italic> UniProt protein database (UniProtKB version July 2020, containing 25,805 entries) and the instrument type set to Orbitrap. Trypsin was set as the proteolytic enzyme and two missed cleavages were allowed. Carbamidomethylation of cysteine was selected as a fixed modification and N-terminal protein acetylation and methionine oxidation as variable modifications. Reverse sequences were selected for the target-decoy database strategy (<xref ref-type="bibr" rid="bib12">Elias and Gygi, 2010</xref>). The FDR was set to 1% for both proteins and peptides, a minimum peptide length specified for seven amino acids. The ‘match between runs’ feature of MaxQuant was used to transfer identifications to other LC-MS/MS runs based on their masses and retention time and this was also used in quantification experiments. Quantifications were performed with the label-free algorithm in MaxQuant (<xref ref-type="bibr" rid="bib10">Cox et al., 2014</xref>). The Fast LFQ option was switched off. Each sample of total protein extract was treated as a separate ‘experiment’ for quantification. Corresponding E- and S-fractions together were treated as another separate ‘experiment’. Unique+razor values were used for label-free quantification (LFQ). Protein groups identified through target-decoy database strategy (‘Reverse’ column in the MaxQuantproteinGroups file) and proteins not identified by MS/MS spectrum (‘Only identified by site’ column in the MaxQuantproteinGroups file) were removed and not included in any subsequent analysis.</p><p>The overall protein intensity for total extract samples was estimated as a sum of MaxQuant LFQ values for unique and razor-detected peptides. For each S-fraction sample and corresponding E-fraction sample, the proportional coefficients for LFQ values of unique and razor-detected peptides of each ‘experiment’ were computed according to <xref ref-type="bibr" rid="bib10">Cox et al., 2014</xref>, using the script for R software (version 4.0.5 for Windows) and the values in the MaxQuant evidence file. After the estimation of the proportional coefficients for each fraction, the overall protein MS intensity for each fraction was estimated as a sum of normalized LFQ values for unique and razor-detected peptides. The MS proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (<xref ref-type="bibr" rid="bib49">Perez-Riverol et al., 2025</xref>) partner repository with the dataset identifier PXD060305 and are accessible with token 65Dd5LEEHtWr.</p></sec><sec id="s4-7"><title>Bioinformatic analysis and statistics</title><p>Normalized (<xref ref-type="bibr" rid="bib23">Hynek et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Cejnar et al., 2022</xref>) log 2-transformed MS intensity data quantified as described above were uploaded for bioinformatic analysis into the bioinformatics platform Perseus (1.6.10.43 version; <xref ref-type="bibr" rid="bib63">Tyanova et al., 2016</xref>). The used annotations were: gene ontology, biological process, molecular function, cellular component, KEGG pathway databases, matrisome database (<xref ref-type="bibr" rid="bib42">Naba et al., 2012</xref>; <xref ref-type="bibr" rid="bib58">Shao et al., 2020</xref>), previously published cell-type-specific protein and gene expression signatures of liver cells (<xref ref-type="bibr" rid="bib4">Azimifar et al., 2014</xref>) and leukocyte populations (<xref ref-type="bibr" rid="bib16">Gautier et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Miller et al., 2012</xref>; <xref ref-type="bibr" rid="bib26">Jojic et al., 2013</xref>), annotations, ‘location’, and ‘function’ from IPA (<xref ref-type="bibr" rid="bib33">Krämer et al., 2014</xref>) annotation (IPA, QIAGEN Inc, <ext-link ext-link-type="uri" xlink:href="https://www.qiagenbioinformatics.com/products/ingenuitypathway">https://www.qiagenbioinformatics.com/products/ingenuitypathway</ext-link>) and MRTF target genes (<xref ref-type="bibr" rid="bib13">Esnault et al., 2014</xref>). All data analyzed were first log 2-transformed. The PCA was performed in Perseus software with the built-in tool and all data imputed by random selection from a normal distribution generated at 1.8 standard deviations subtracted from the mean of the total intensity distribution and a width of 0.3 standard deviations. For Total proteome sample analysis, data from Total samples were first filtered for proteins expressed in at least one group (control, and times T1, T2, T3, or T4) with at least five identified values in both models (CCl<sub>4</sub> and DDC) together. For subsequent analyses we also similarly filtered Total proteome samples in each model separately. Missing values among identified proteins in analyzed datasets were imputed into Perseus as described above. Proteins significantly differentially expressed in the Total proteome of each fibrosis model separately (analyses in <xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref>) were defined as proteins with a minimum 1.5-fold significant change in expression in the highest fibrosis time point (T2) over the average expression in controls (t-test at a BH FDR&lt;0.05). Unsupervised hierarchical cluster analyses of averages of z-scored MS intensities of identified proteins were performed with Euclidean distance and complete linkage in the Perseus software with built-in cluster enrichment analysis. To extract individual cell-type dynamics from the proteomics data, we used previously published cell-type-specific signatures (<xref ref-type="bibr" rid="bib4">Azimifar et al., 2014</xref>; <xref ref-type="bibr" rid="bib16">Gautier et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Miller et al., 2012</xref>; <xref ref-type="bibr" rid="bib26">Jojic et al., 2013</xref>). For each of this way identified proteins, average z-scored MS intensity in each time point was calculated and the signature proteins of each cell type were together plotted in each time point as box plots, with 25th and 75th percentile indicated as explained below.</p><p>All graphs and statistical tests indicated in graphs were performed using GraphPad Prism version 9.3.1 (GraphPad Software, Boston, MA, USA, <ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link>). All results are presented as mean ± SEM. In the box plots, the box represents the 25th and 75th percentile with the median indicated; whiskers reach the last data point; dots indicate means of independent experiments. Normally distributed parametrical data were analyzed by two-tailed unpaired Student’s t-test. A comparison between multiple groups was performed using one-way ANOVA with Tukey’s multiple comparison test. Data distribution was assumed to be normal, but this was not formally tested. Statistical tests used are specified in the figure legends. Statistical significance was determined at the level of *, p&lt;0.05; **, p&lt;0.01; <sup>†</sup>, p&lt;0.001.</p></sec><sec id="s4-8"><title>E-fraction analysis</title><p>Proteins identified in E-fraction samples were first filtered and imputed as described above for each model separately. All proteins detected in S-fraction were also imputed in Perseus as described above and median S-fraction MS intensity value for each protein was calculated. To identify proteins with change in solubility, which would be specifically enriched in E-fraction, we calculated a ratio of the MS intensity of each protein replicate in E-fraction to the median of MS intensity of this protein in S-fraction and selected those with a minimum threefold higher expression in E- than S-fraction in at least one time point (control, T1-T4). From these, proteins with a significant change in time identified by ANOVA with BH FDR&lt;0.05 represented insoluble fraction proteins, i.e., E-fraction proteome. Unsupervised hierarchical clustering of MS intensity ratios of the abundance of these proteins in E- to S-fraction was performed in Perseus as described above to identify changes in protein solubility over time with disease progression and recovery.</p></sec><sec id="s4-9"><title>Ingenuity Pathway Analysis</title><p>We used the IPA (<xref ref-type="bibr" rid="bib33">Krämer et al., 2014</xref>) to identify predicted upstream transcriptional regulators and growth factors and downstream canonical signaling pathways elicited by groups of proteins identified in individual analyses. Transcriptional regulators and growth factors were identified in upstream regulator analysis with protein overlap p-value&gt;3 (log 10) and activation z-score&gt;|2.5|. Canonical pathways were considered only with overlap p-value&gt;3 (log 10) and activation z-score&gt;|2|.</p></sec><sec id="s4-10"><title>Correlation analysis</title><p>The MS protein temporal abundance change profile of each protein was correlated with the fibrosis area change for proteins of Total proteome and E-fraction proteome in each model. To do this, we calculated the mean value of log 2-transformed and imputed MS intensities for each protein in controls and subtracted it from the log 2-transformed MS intensity for each protein at each time point in individual mice. This way obtained temporal abundance profile ratio of each protein was then correlated to the temporal profile of fibrosis area (calculated as a percentage of sirius red positive areas in each mouse at each time point after subtracting the background calculated as the average sirius red positive area in control livers) using Pearson correlation coefficient separately for each model. We then plotted the correlation linear regression slope against the Pearson correlation coefficient in each of the proteomes for each of the identified proteins (<xref ref-type="fig" rid="fig6">Figure 6B–D</xref>). The significance of dependency (slope’s p-value) for each protein was corrected by BH multiple comparisons test (p = 0.05). Analysis of DDC-induced differentially expressed proteins did not result in any proteins significantly correlating with collagen deposition in either of the proteomes (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3</xref>). This is most likely a consequence of considerable variability in the scar tissue deposition in this model at each time point.</p></sec><sec id="s4-11"><title>Atomic force microscopy</title><p>AFM was performed on 30-μm-thick liver sections shortly fixed with 4% PFA in PBS, as previously described (<xref ref-type="bibr" rid="bib46">Ojha et al., 2022</xref>). Briefly, glass slides containing fixed liver sections covered with PBS were placed onto a combined AFM/inverted optical microscope (JPK NanoWizard 3XP; Bruker Nano Nano Surfaces Division, Santa Barbara, CA, USA/Olympus IX81; Olympus C&amp;S, Prague, Czech Republic) equipped with a custom-made dual-polarization motorized filter allowing precise localization areas of interest: collagen-rich fibrotic areas, areas of injured, and interface hepatocytes (<xref ref-type="bibr" rid="bib6">Ben-Moshe et al., 2022</xref>). To characterize the mechanical properties of livers, we used an SD-qp-BioT-TL-10 cantilever (S/N-73750F05, Nanosensors, NanoAndMore GmbH, Wetzlar, Germany) with a nominal sprint constant of 0.09 N/m modified with a 5.7 μm melamine polymer bead (Microparticles GmbH, Germany). Before each experiment, the cantilever spring constant was calibrated using the thermal noise method while immersed in PBS. Using the force mapping method, we measured 30 ×100 μm<sup>2</sup> (10 × 36 pixels) defined areas precisely located by polarized microscopy. We analyzed seven areas (measured from two sections per mouse) obtained from three different mice for each time point (control, T1, T2, and T4). Data were further processed with open-source software ‘AtomicJ’ (<xref ref-type="bibr" rid="bib21">Hermanowicz et al., 2014</xref>) using a Poisson ratio of 0.45 (<xref ref-type="bibr" rid="bib5">Barnes et al., 2007</xref>). All data were further analyzed in GraphPad Prism software and are presented as frequency distribution histograms. Statistical analyses were performed on frequency distribution histograms using the Kruskal-Wallis test followed by Dunn’s multiple comparisons post-testing. To correlate the AFM data with protein MS abundance change during fibrosis development and resolution, we averaged median Young’s moduli for each analyzed area in each measured mouse. After subtraction of mean control Young’s moduli, the slope and p-value for the dependency of the stiffness of the area on the protein MS intensities were determined, and the p-value was corrected by BH multiple comparisons test (p&lt;0.05).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Funding acquisition, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Visualization, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con7"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Supervision, Funding acquisition, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The use of completely anonymized archived liver tissue samples for research purposes has been approved by the Ethical Committee of the Institute of Experimental and Clinical Medicine and Thomayer University Hospital, Prague, Czech Republic. Written informed consent was obtained from all patients enrolled in the study. All research was conducted in accordance with both the Declarations of Helsinki and Istanbul.</p></fn><fn fn-type="other"><p>All animal experiments were performed in accordance with an animal protocol approved by the Animal Care Committee of The Institute of Molecular Genetics and according to EU Directive 2010/63/EU for animal experiments.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-98023-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository (<xref ref-type="bibr" rid="bib49">Perez-Riverol et al., 2025</xref>) with the dataset identifier PXD060305.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Jirouskova</surname><given-names>M</given-names></name><name><surname>Harant</surname><given-names>K</given-names></name><name><surname>Cejnar</surname><given-names>P</given-names></name><name><surname>Ojha</surname><given-names>S</given-names></name><name><surname>Korelova</surname><given-names>K</given-names></name><name><surname>Sarnova</surname><given-names>L</given-names></name><name><surname>Sticova</surname><given-names>E</given-names></name><name><surname>Mayr</surname><given-names>CH</given-names></name><name><surname>Schiller</surname><given-names>HB</given-names></name><name><surname>Gregor</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>Dynamics of compartment-specific proteomic landscapes of hepatotoxic and cholestatic models of liver fibrosis</data-title><source>PRIDE</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD060305">PXD060305</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We would like to thank SM Meier-Menches (University of Vienna, Austria) and J Masek (Charles University, Prague, Czech Republic) for critical reading of the manuscript and D Hadraba (Institute of Physiology, Prague, Czech Republic) for sharing his expertise. We further acknowledge the Light Microscopy Core Facility, IMG CAS, Prague, Czech Republic for support with the microscopy imaging presented herein. We would also like to thank V Getmanchuk – Zaporoshchenko for detailed proofreading of the final manuscript. This work was supported by the Grant Agency of the Czech Republic (18-02699S and 21-21736S); the Grant Agency of the Ministry of Health of the Czech Republic (NU21-04-00100); the Institutional Research Project of the Czech Academy of Sciences (RVO 68378050); the National Institute for Cancer Research (Program EXCELES, LX22NPO5102) – funded by the European Union – Next Generation EU; the Grant Agency of Charles University (273723), and MEYS CR projects (LM2023050, LM2018126, LQ1604 NPU II, LO1419, and LM2015040). We acknowledge CF Nanobiotechnology of CIISB, Instruct-CZ Centre, supported by MEYS CR (LM2023042) and European Regional Development Fund-Project 'Innovation of Czech Infrastructure for Integrative Structural Biology' (No. CZ.02.01.01/00/23_015/0008175). The funding sources were not involved in the study design, data collection and analysis, decision to publish, or preparation of the article.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acun</surname><given-names>A</given-names></name><name><surname>Oganesyan</surname><given-names>R</given-names></name><name><surname>Uygun</surname><given-names>K</given-names></name><name><surname>Yeh</surname><given-names>H</given-names></name><name><surname>Yarmush</surname><given-names>ML</given-names></name><name><surname>Uygun</surname><given-names>BE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Liver donor age affects hepatocyte function through age-dependent changes in decellularized liver matrix</article-title><source>Biomaterials</source><volume>270</volume><elocation-id>120689</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.120689</pub-id><pub-id pub-id-type="pmid">33524812</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aigelsreiter</surname><given-names>A</given-names></name><name><surname>Janig</surname><given-names>E</given-names></name><name><surname>Sostaric</surname><given-names>J</given-names></name><name><surname>Pichler</surname><given-names>M</given-names></name><name><surname>Unterthor</surname><given-names>D</given-names></name><name><surname>Halasz</surname><given-names>J</given-names></name><name><surname>Lackner</surname><given-names>C</given-names></name><name><surname>Zatloukal</surname><given-names>K</given-names></name><name><surname>Denk</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Clusterin expression in cholestasis, hepatocellular carcinoma and liver fibrosis</article-title><source>Histopathology</source><volume>54</volume><fpage>561</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2559.2009.03258.x</pub-id><pub-id pub-id-type="pmid">19413638</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>SY</given-names></name><name><surname>Jang</surname><given-names>YJ</given-names></name><name><surname>Lim</surname><given-names>HJ</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Do</surname><given-names>BR</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Park</surname><given-names>HK</given-names></name><name><surname>Kim</surname><given-names>OH</given-names></name><name><surname>Song</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Milk fat globule-EGF factor 8, secreted by mesenchymal stem cells, protects against liver fibrosis in mice</article-title><source>Gastroenterology</source><volume>152</volume><fpage>1174</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.12.003</pub-id><pub-id pub-id-type="pmid">27956229</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azimifar</surname><given-names>SB</given-names></name><name><surname>Nagaraj</surname><given-names>N</given-names></name><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cell-type-resolved quantitative proteomics of murine liver</article-title><source>Cell Metabolism</source><volume>20</volume><fpage>1076</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2014.11.002</pub-id><pub-id pub-id-type="pmid">25470552</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>SL</given-names></name><name><surname>Lyshchik</surname><given-names>A</given-names></name><name><surname>Washington</surname><given-names>MK</given-names></name><name><surname>Gore</surname><given-names>JC</given-names></name><name><surname>Miga</surname><given-names>MI</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Development of a mechanical testing assay for fibrotic murine liver</article-title><source>Medical Physics</source><volume>34</volume><fpage>4439</fpage><lpage>4450</lpage><pub-id pub-id-type="doi">10.1118/1.2795665</pub-id><pub-id pub-id-type="pmid">18072508</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Moshe</surname><given-names>S</given-names></name><name><surname>Veg</surname><given-names>T</given-names></name><name><surname>Manco</surname><given-names>R</given-names></name><name><surname>Dan</surname><given-names>S</given-names></name><name><surname>Papinutti</surname><given-names>D</given-names></name><name><surname>Lifshitz</surname><given-names>A</given-names></name><name><surname>Kolodziejczyk</surname><given-names>AA</given-names></name><name><surname>Bahar Halpern</surname><given-names>K</given-names></name><name><surname>Elinav</surname><given-names>E</given-names></name><name><surname>Itzkovitz</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The spatiotemporal program of zonal liver regeneration following acute injury</article-title><source>Cell Stem Cell</source><volume>29</volume><fpage>973</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2022.04.008</pub-id><pub-id pub-id-type="pmid">35659879</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cejnar</surname><given-names>P</given-names></name><name><surname>Smirnova</surname><given-names>TA</given-names></name><name><surname>Kuckova</surname><given-names>S</given-names></name><name><surname>Prochazka</surname><given-names>A</given-names></name><name><surname>Zak</surname><given-names>I</given-names></name><name><surname>Harant</surname><given-names>K</given-names></name><name><surname>Zakharov</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Acute and chronic blood serum proteome changes in patients with methanol poisoning</article-title><source>Scientific Reports</source><volume>12</volume><elocation-id>21379</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-25492-9</pub-id><pub-id pub-id-type="pmid">36494437</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couvelard</surname><given-names>A</given-names></name><name><surname>Scoazec</surname><given-names>JY</given-names></name><name><surname>Feldmann</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Expression of cell-cell and cell-matrix adhesion proteins by sinusoidal endothelial cells in the normal and cirrhotic human liver</article-title><source>The American Journal of Pathology</source><volume>143</volume><fpage>738</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">8362973</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification</article-title><source>Nature Biotechnology</source><volume>26</volume><fpage>1367</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1038/nbt.1511</pub-id><pub-id pub-id-type="pmid">19029910</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>Hein</surname><given-names>MY</given-names></name><name><surname>Luber</surname><given-names>CA</given-names></name><name><surname>Paron</surname><given-names>I</given-names></name><name><surname>Nagaraj</surname><given-names>N</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>13</volume><fpage>2513</fpage><lpage>2526</lpage><pub-id pub-id-type="doi">10.1074/mcp.M113.031591</pub-id><pub-id pub-id-type="pmid">24942700</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Didiasova</surname><given-names>M</given-names></name><name><surname>Schaefer</surname><given-names>L</given-names></name><name><surname>Wygrecka</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>When place matters: shuttling of enolase-1 across cellular compartments</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>7</volume><elocation-id>61</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2019.00061</pub-id><pub-id pub-id-type="pmid">31106201</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>JE</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Target-decoy search strategy for mass spectrometry-based proteomics</article-title><source>Methods in Molecular Biology</source><volume>604</volume><fpage>55</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1007/978-1-60761-444-9_5</pub-id><pub-id pub-id-type="pmid">20013364</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esnault</surname><given-names>C</given-names></name><name><surname>Stewart</surname><given-names>A</given-names></name><name><surname>Gualdrini</surname><given-names>F</given-names></name><name><surname>East</surname><given-names>P</given-names></name><name><surname>Horswell</surname><given-names>S</given-names></name><name><surname>Matthews</surname><given-names>N</given-names></name><name><surname>Treisman</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Rho-actin signaling to the MRTF coactivators dominates the immediate transcriptional response to serum in fibroblasts</article-title><source>Genes &amp; Development</source><volume>28</volume><fpage>943</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1101/gad.239327.114</pub-id><pub-id pub-id-type="pmid">24732378</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Hammad</surname><given-names>S</given-names></name><name><surname>Longerich</surname><given-names>T</given-names></name><name><surname>Hausser</surname><given-names>I</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lian</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Yi</surname><given-names>C</given-names></name><name><surname>Ling</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Cong</surname><given-names>M</given-names></name><name><surname>You</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Hui</surname><given-names>L</given-names></name><name><surname>Dooley</surname><given-names>S</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>ECM1 prevents activation of transforming growth factor β, hepatic stellate cells, and fibrogenesis in mice</article-title><source>Gastroenterology</source><volume>157</volume><fpage>1352</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2019.07.036</pub-id><pub-id pub-id-type="pmid">31362006</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fickert</surname><given-names>P</given-names></name><name><surname>Stöger</surname><given-names>U</given-names></name><name><surname>Fuchsbichler</surname><given-names>A</given-names></name><name><surname>Moustafa</surname><given-names>T</given-names></name><name><surname>Marschall</surname><given-names>H-U</given-names></name><name><surname>Weiglein</surname><given-names>AH</given-names></name><name><surname>Tsybrovskyy</surname><given-names>O</given-names></name><name><surname>Jaeschke</surname><given-names>H</given-names></name><name><surname>Zatloukal</surname><given-names>K</given-names></name><name><surname>Denk</surname><given-names>H</given-names></name><name><surname>Trauner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis</article-title><source>The American Journal of Pathology</source><volume>171</volume><fpage>525</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2007.061133</pub-id><pub-id pub-id-type="pmid">17600122</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautier</surname><given-names>EL</given-names></name><name><surname>Shay</surname><given-names>T</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Greter</surname><given-names>M</given-names></name><name><surname>Jakubzick</surname><given-names>C</given-names></name><name><surname>Ivanov</surname><given-names>S</given-names></name><name><surname>Helft</surname><given-names>J</given-names></name><name><surname>Chow</surname><given-names>A</given-names></name><name><surname>Elpek</surname><given-names>KG</given-names></name><name><surname>Gordonov</surname><given-names>S</given-names></name><name><surname>Mazloom</surname><given-names>AR</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name><name><surname>Chua</surname><given-names>W-J</given-names></name><name><surname>Hansen</surname><given-names>TH</given-names></name><name><surname>Turley</surname><given-names>SJ</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Randolph</surname><given-names>GJ</given-names></name><collab>Immunological Genome Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages</article-title><source>Nature Immunology</source><volume>13</volume><fpage>1118</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1038/ni.2419</pub-id><pub-id pub-id-type="pmid">23023392</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georges</surname><given-names>PC</given-names></name><name><surname>Hui</surname><given-names>JJ</given-names></name><name><surname>Gombos</surname><given-names>Z</given-names></name><name><surname>McCormick</surname><given-names>ME</given-names></name><name><surname>Wang</surname><given-names>AY</given-names></name><name><surname>Uemura</surname><given-names>M</given-names></name><name><surname>Mick</surname><given-names>R</given-names></name><name><surname>Janmey</surname><given-names>PA</given-names></name><name><surname>Furth</surname><given-names>EE</given-names></name><name><surname>Wells</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis</article-title><source>American Journal of Physiology. Gastrointestinal and Liver Physiology</source><volume>293</volume><fpage>G1147</fpage><lpage>G1154</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00032.2007</pub-id><pub-id pub-id-type="pmid">17932231</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghallab</surname><given-names>A</given-names></name><name><surname>Myllys</surname><given-names>M</given-names></name><name><surname>Holland</surname><given-names>CH</given-names></name><name><surname>Zaza</surname><given-names>A</given-names></name><name><surname>Murad</surname><given-names>W</given-names></name><name><surname>Hassan</surname><given-names>R</given-names></name><name><surname>Ahmed</surname><given-names>YA</given-names></name><name><surname>Abbas</surname><given-names>T</given-names></name><name><surname>Abdelrahim</surname><given-names>EA</given-names></name><name><surname>Schneider</surname><given-names>KM</given-names></name><name><surname>Matz-Soja</surname><given-names>M</given-names></name><name><surname>Reinders</surname><given-names>J</given-names></name><name><surname>Gebhardt</surname><given-names>R</given-names></name><name><surname>Berres</surname><given-names>M-L</given-names></name><name><surname>Hatting</surname><given-names>M</given-names></name><name><surname>Drasdo</surname><given-names>D</given-names></name><name><surname>Saez-Rodriguez</surname><given-names>J</given-names></name><name><surname>Trautwein</surname><given-names>C</given-names></name><name><surname>Hengstler</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Influence of liver fibrosis on lobular zonation</article-title><source>Cells</source><volume>8</volume><elocation-id>1556</elocation-id><pub-id pub-id-type="doi">10.3390/cells8121556</pub-id><pub-id pub-id-type="pmid">31810365</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebert</surname><given-names>AS</given-names></name><name><surname>Richards</surname><given-names>AL</given-names></name><name><surname>Bailey</surname><given-names>DJ</given-names></name><name><surname>Ulbrich</surname><given-names>A</given-names></name><name><surname>Coughlin</surname><given-names>EE</given-names></name><name><surname>Westphall</surname><given-names>MS</given-names></name><name><surname>Coon</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The one hour yeast proteome</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>13</volume><fpage>339</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1074/mcp.M113.034769</pub-id><pub-id pub-id-type="pmid">24143002</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>NC</given-names></name><name><surname>Rieder</surname><given-names>F</given-names></name><name><surname>Wynn</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Fibrosis: from mechanisms to medicines</article-title><source>Nature</source><volume>587</volume><fpage>555</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2938-9</pub-id><pub-id pub-id-type="pmid">33239795</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermanowicz</surname><given-names>P</given-names></name><name><surname>Sarna</surname><given-names>M</given-names></name><name><surname>Burda</surname><given-names>K</given-names></name><name><surname>Gabryś</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>AtomicJ: an open source software for analysis of force curves</article-title><source>The Review of Scientific Instruments</source><volume>85</volume><elocation-id>063703</elocation-id><pub-id pub-id-type="doi">10.1063/1.4881683</pub-id><pub-id pub-id-type="pmid">24985823</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>CS</given-names></name><name><surname>Moggridge</surname><given-names>S</given-names></name><name><surname>Müller</surname><given-names>T</given-names></name><name><surname>Sorensen</surname><given-names>PH</given-names></name><name><surname>Morin</surname><given-names>GB</given-names></name><name><surname>Krijgsveld</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Single-pot, solid-phase-enhanced sample preparation for proteomics experiments</article-title><source>Nature Protocols</source><volume>14</volume><fpage>68</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/s41596-018-0082-x</pub-id><pub-id pub-id-type="pmid">30464214</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hynek</surname><given-names>R</given-names></name><name><surname>Michalus</surname><given-names>I</given-names></name><name><surname>Cejnar</surname><given-names>P</given-names></name><name><surname>Šantrůček</surname><given-names>J</given-names></name><name><surname>Seidlová</surname><given-names>S</given-names></name><name><surname>Kučková</surname><given-names>Š</given-names></name><name><surname>Sázelová</surname><given-names>P</given-names></name><name><surname>Kašička</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>In-bone protein digestion followed by LC-MS/MS peptide analysis as a new way towards the routine proteomic characterization of human maxillary and mandibular bone tissue in oral surgery</article-title><source>Electrophoresis</source><volume>42</volume><fpage>2552</fpage><lpage>2562</lpage><pub-id pub-id-type="doi">10.1002/elps.202100211</pub-id><pub-id pub-id-type="pmid">34453862</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hynes</surname><given-names>RO</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The extracellular matrix: not just pretty fibrils</article-title><source>Science</source><volume>326</volume><fpage>1216</fpage><lpage>1219</lpage><pub-id pub-id-type="doi">10.1126/science.1176009</pub-id><pub-id pub-id-type="pmid">19965464</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>G</given-names></name><name><surname>Howe</surname><given-names>PH</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Transforming growth factor beta regulates clusterin gene expression via modulation of transcription factor c-Fos</article-title><source>European Journal of Biochemistry</source><volume>263</volume><fpage>534</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1046/j.1432-1327.1999.00533.x</pub-id><pub-id pub-id-type="pmid">10406964</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jojic</surname><given-names>V</given-names></name><name><surname>Shay</surname><given-names>T</given-names></name><name><surname>Sylvia</surname><given-names>K</given-names></name><name><surname>Zuk</surname><given-names>O</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Koller</surname><given-names>D</given-names></name><collab>Immunological Genome Project Consortium</collab><name><surname>Best</surname><given-names>AJ</given-names></name><name><surname>Knell</surname><given-names>J</given-names></name><name><surname>Goldrath</surname><given-names>A</given-names></name><name><surname>Joic</surname><given-names>V</given-names></name><name><surname>Koller</surname><given-names>D</given-names></name><name><surname>Shay</surname><given-names>T</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>N</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Brenner</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>F</given-names></name><name><surname>Rao</surname><given-names>TN</given-names></name><name><surname>Wagers</surname><given-names>A</given-names></name><name><surname>Heng</surname><given-names>T</given-names></name><name><surname>Ericson</surname><given-names>J</given-names></name><name><surname>Rothamel</surname><given-names>K</given-names></name><name><surname>Ortiz-Lopez</surname><given-names>A</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name><name><surname>Bezman</surname><given-names>NA</given-names></name><name><surname>Sun</surname><given-names>JC</given-names></name><name><surname>Min-Oo</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>CC</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>B</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Gautier</surname><given-names>EL</given-names></name><name><surname>Jakubzick</surname><given-names>C</given-names></name><name><surname>Randolph</surname><given-names>GJ</given-names></name><name><surname>Monach</surname><given-names>P</given-names></name><name><surname>Blair</surname><given-names>DA</given-names></name><name><surname>Dustin</surname><given-names>ML</given-names></name><name><surname>Shinton</surname><given-names>SA</given-names></name><name><surname>Hardy</surname><given-names>RR</given-names></name><name><surname>Laidlaw</surname><given-names>D</given-names></name><name><surname>Collins</surname><given-names>J</given-names></name><name><surname>Gazit</surname><given-names>R</given-names></name><name><surname>Rossi</surname><given-names>DJ</given-names></name><name><surname>Malhotra</surname><given-names>N</given-names></name><name><surname>Sylvia</surname><given-names>K</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Kreslavsky</surname><given-names>T</given-names></name><name><surname>Fletcher</surname><given-names>A</given-names></name><name><surname>Elpek</surname><given-names>K</given-names></name><name><surname>Bellemarte-Pelletier</surname><given-names>A</given-names></name><name><surname>Malhotra</surname><given-names>D</given-names></name><name><surname>Turley</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Identification of transcriptional regulators in the mouse immune system</article-title><source>Nature Immunology</source><volume>14</volume><fpage>633</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1038/ni.2587</pub-id><pub-id pub-id-type="pmid">23624555</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>N</given-names></name><name><surname>Kopec</surname><given-names>AK</given-names></name><name><surname>Ray</surname><given-names>JL</given-names></name><name><surname>Cline-Fedewa</surname><given-names>H</given-names></name><name><surname>Nawabi</surname><given-names>A</given-names></name><name><surname>Schmitt</surname><given-names>T</given-names></name><name><surname>Nault</surname><given-names>R</given-names></name><name><surname>Zacharewski</surname><given-names>TR</given-names></name><name><surname>Rockwell</surname><given-names>CE</given-names></name><name><surname>Flick</surname><given-names>MJ</given-names></name><name><surname>Luyendyk</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Fibrin deposition following bile duct injury limits fibrosis through an αMβ2-dependent mechanism</article-title><source>Blood</source><volume>127</volume><fpage>2751</fpage><lpage>2762</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-09-670703</pub-id><pub-id pub-id-type="pmid">26921287</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlsen</surname><given-names>TH</given-names></name><name><surname>Sheron</surname><given-names>N</given-names></name><name><surname>Zelber-Sagi</surname><given-names>S</given-names></name><name><surname>Carrieri</surname><given-names>P</given-names></name><name><surname>Dusheiko</surname><given-names>G</given-names></name><name><surname>Bugianesi</surname><given-names>E</given-names></name><name><surname>Pryke</surname><given-names>R</given-names></name><name><surname>Hutchinson</surname><given-names>SJ</given-names></name><name><surname>Sangro</surname><given-names>B</given-names></name><name><surname>Martin</surname><given-names>NK</given-names></name><name><surname>Cecchini</surname><given-names>M</given-names></name><name><surname>Dirac</surname><given-names>MA</given-names></name><name><surname>Belloni</surname><given-names>A</given-names></name><name><surname>Serra-Burriel</surname><given-names>M</given-names></name><name><surname>Ponsioen</surname><given-names>CY</given-names></name><name><surname>Sheena</surname><given-names>B</given-names></name><name><surname>Lerouge</surname><given-names>A</given-names></name><name><surname>Devaux</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>N</given-names></name><name><surname>Hellard</surname><given-names>M</given-names></name><name><surname>Verkade</surname><given-names>HJ</given-names></name><name><surname>Sturm</surname><given-names>E</given-names></name><name><surname>Marchesini</surname><given-names>G</given-names></name><name><surname>Yki-Järvinen</surname><given-names>H</given-names></name><name><surname>Byrne</surname><given-names>CD</given-names></name><name><surname>Targher</surname><given-names>G</given-names></name><name><surname>Tur-Sinai</surname><given-names>A</given-names></name><name><surname>Barrett</surname><given-names>D</given-names></name><name><surname>Ninburg</surname><given-names>M</given-names></name><name><surname>Reic</surname><given-names>T</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Rhodes</surname><given-names>T</given-names></name><name><surname>Treloar</surname><given-names>C</given-names></name><name><surname>Petersen</surname><given-names>C</given-names></name><name><surname>Schramm</surname><given-names>C</given-names></name><name><surname>Flisiak</surname><given-names>R</given-names></name><name><surname>Simonova</surname><given-names>MY</given-names></name><name><surname>Pares</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>P</given-names></name><name><surname>Cucchetti</surname><given-names>A</given-names></name><name><surname>Graupera</surname><given-names>I</given-names></name><name><surname>Lionis</surname><given-names>C</given-names></name><name><surname>Pose</surname><given-names>E</given-names></name><name><surname>Fabrellas</surname><given-names>N</given-names></name><name><surname>Ma</surname><given-names>AT</given-names></name><name><surname>Mendive</surname><given-names>JM</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Rutter</surname><given-names>H</given-names></name><name><surname>Cortez-Pinto</surname><given-names>H</given-names></name><name><surname>Kelly</surname><given-names>D</given-names></name><name><surname>Burton</surname><given-names>R</given-names></name><name><surname>Lazarus</surname><given-names>JV</given-names></name><name><surname>Ginès</surname><given-names>P</given-names></name><name><surname>Buti</surname><given-names>M</given-names></name><name><surname>Newsome</surname><given-names>PN</given-names></name><name><surname>Burra</surname><given-names>P</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The EASL-lancet liver commission: protecting the next generation of Europeans against liver disease complications and premature mortality</article-title><source>Lancet</source><volume>399</volume><fpage>61</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)01701-3</pub-id><pub-id pub-id-type="pmid">34863359</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kendall</surname><given-names>TJ</given-names></name><name><surname>Dolman</surname><given-names>GE</given-names></name><name><surname>Duff</surname><given-names>CM</given-names></name><name><surname>Paish</surname><given-names>EC</given-names></name><name><surname>Zaitoun</surname><given-names>A</given-names></name><name><surname>Irving</surname><given-names>W</given-names></name><name><surname>Fallowfield</surname><given-names>JA</given-names></name><name><surname>Guha</surname><given-names>IN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease</article-title><source>Histopathology</source><volume>73</volume><fpage>90</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1111/his.13499</pub-id><pub-id pub-id-type="pmid">29464815</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kisseleva</surname><given-names>T</given-names></name><name><surname>Brenner</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Molecular and cellular mechanisms of liver fibrosis and its regression</article-title><source>Nature Reviews. Gastroenterology &amp; Hepatology</source><volume>18</volume><fpage>151</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1038/s41575-020-00372-7</pub-id><pub-id pub-id-type="pmid">33128017</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klaas</surname><given-names>M</given-names></name><name><surname>Kangur</surname><given-names>T</given-names></name><name><surname>Viil</surname><given-names>J</given-names></name><name><surname>Mäemets-Allas</surname><given-names>K</given-names></name><name><surname>Minajeva</surname><given-names>A</given-names></name><name><surname>Vadi</surname><given-names>K</given-names></name><name><surname>Antsov</surname><given-names>M</given-names></name><name><surname>Lapidus</surname><given-names>N</given-names></name><name><surname>Järvekülg</surname><given-names>M</given-names></name><name><surname>Jaks</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The alterations in the extracellular matrix composition guide the repair of damaged liver tissue</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>27398</elocation-id><pub-id pub-id-type="doi">10.1038/srep27398</pub-id><pub-id pub-id-type="pmid">27264108</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kömüves</surname><given-names>LG</given-names></name><name><surname>Feren</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>AL</given-names></name><name><surname>Fodor</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Expression of epidermal growth factor and its receptor in cirrhotic liver disease</article-title><source>The Journal of Histochemistry and Cytochemistry</source><volume>48</volume><fpage>821</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1177/002215540004800610</pub-id><pub-id pub-id-type="pmid">10820155</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krämer</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>J</given-names></name><name><surname>Pollard</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Tugendreich</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Causal analysis approaches in Ingenuity pathway analysis</article-title><source>Bioinformatics</source><volume>30</volume><fpage>523</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt703</pub-id><pub-id pub-id-type="pmid">24336805</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>KKY</given-names></name><name><surname>Shang</surname><given-names>S</given-names></name><name><surname>Lohia</surname><given-names>N</given-names></name><name><surname>Booth</surname><given-names>GC</given-names></name><name><surname>Masse</surname><given-names>DJ</given-names></name><name><surname>Fausto</surname><given-names>N</given-names></name><name><surname>Campbell</surname><given-names>JS</given-names></name><name><surname>Beretta</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models</article-title><source>PLOS Genetics</source><volume>7</volume><elocation-id>e1002147</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1002147</pub-id><pub-id pub-id-type="pmid">21731504</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Weng</surname><given-names>H</given-names></name><name><surname>Hellerbrand</surname><given-names>C</given-names></name><name><surname>ten Dijke</surname><given-names>P</given-names></name><name><surname>Dooley</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Animal models of chronic liver diseases</article-title><source>American Journal of Physiology. Gastrointestinal and Liver Physiology</source><volume>304</volume><fpage>G449</fpage><lpage>G468</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00199.2012</pub-id><pub-id pub-id-type="pmid">23275613</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mak</surname><given-names>KM</given-names></name><name><surname>Chen</surname><given-names>LL</given-names></name><name><surname>Lee</surname><given-names>TF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Codistribution of collagen type IV and laminin in liver fibrosis of elderly cadavers: immunohistochemical marker of perisinusoidal basement membrane formation</article-title><source>The Anatomical Record</source><volume>296</volume><fpage>953</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1002/ar.22694</pub-id><pub-id pub-id-type="pmid">23596149</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manco</surname><given-names>R</given-names></name><name><surname>Clerbaux</surname><given-names>L-A</given-names></name><name><surname>Verhulst</surname><given-names>S</given-names></name><name><surname>Bou Nader</surname><given-names>M</given-names></name><name><surname>Sempoux</surname><given-names>C</given-names></name><name><surname>Ambroise</surname><given-names>J</given-names></name><name><surname>Bearzatto</surname><given-names>B</given-names></name><name><surname>Gala</surname><given-names>JL</given-names></name><name><surname>Horsmans</surname><given-names>Y</given-names></name><name><surname>van Grunsven</surname><given-names>L</given-names></name><name><surname>Desdouets</surname><given-names>C</given-names></name><name><surname>Leclercq</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Reactive cholangiocytes differentiate into proliferative hepatocytes with efficient DNA repair in mice with chronic liver injury</article-title><source>Journal of Hepatology</source><volume>70</volume><fpage>1180</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.02.003</pub-id><pub-id pub-id-type="pmid">30794890</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massey</surname><given-names>VL</given-names></name><name><surname>Dolin</surname><given-names>CE</given-names></name><name><surname>Poole</surname><given-names>LG</given-names></name><name><surname>Hudson</surname><given-names>SV</given-names></name><name><surname>Siow</surname><given-names>DL</given-names></name><name><surname>Brock</surname><given-names>GN</given-names></name><name><surname>Merchant</surname><given-names>ML</given-names></name><name><surname>Wilkey</surname><given-names>DW</given-names></name><name><surname>Arteel</surname><given-names>GE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The hepatic “matrisome” responds dynamically to injury: characterization of transitional changes to the extracellular matrix in mice</article-title><source>Hepatology</source><volume>65</volume><fpage>969</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1002/hep.28918</pub-id><pub-id pub-id-type="pmid">28035785</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazza</surname><given-names>G</given-names></name><name><surname>Telese</surname><given-names>A</given-names></name><name><surname>Al-Akkad</surname><given-names>W</given-names></name><name><surname>Frenguelli</surname><given-names>L</given-names></name><name><surname>Levi</surname><given-names>A</given-names></name><name><surname>Marrali</surname><given-names>M</given-names></name><name><surname>Longato</surname><given-names>L</given-names></name><name><surname>Thanapirom</surname><given-names>K</given-names></name><name><surname>Vilia</surname><given-names>MG</given-names></name><name><surname>Lombardi</surname><given-names>B</given-names></name><name><surname>Crowley</surname><given-names>C</given-names></name><name><surname>Crawford</surname><given-names>M</given-names></name><name><surname>Karsdal</surname><given-names>MA</given-names></name><name><surname>Leeming</surname><given-names>DJ</given-names></name><name><surname>Marrone</surname><given-names>G</given-names></name><name><surname>Bottcher</surname><given-names>K</given-names></name><name><surname>Robinson</surname><given-names>B</given-names></name><name><surname>Del Rio Hernandez</surname><given-names>A</given-names></name><name><surname>Tamburrino</surname><given-names>D</given-names></name><name><surname>Spoletini</surname><given-names>G</given-names></name><name><surname>Malago</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>AR</given-names></name><name><surname>Godovac-Zimmermann</surname><given-names>J</given-names></name><name><surname>Luong</surname><given-names>TV</given-names></name><name><surname>De Coppi</surname><given-names>P</given-names></name><name><surname>Pinzani</surname><given-names>M</given-names></name><name><surname>Rombouts</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cirrhotic human liver extracellular matrix 3D scaffolds promote smad-dependent TGF-β1 epithelial mesenchymal transition</article-title><source>Cells</source><volume>9</volume><elocation-id>83</elocation-id><pub-id pub-id-type="doi">10.3390/cells9010083</pub-id><pub-id pub-id-type="pmid">31905709</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>JC</given-names></name><name><surname>Brown</surname><given-names>BD</given-names></name><name><surname>Shay</surname><given-names>T</given-names></name><name><surname>Gautier</surname><given-names>EL</given-names></name><name><surname>Jojic</surname><given-names>V</given-names></name><name><surname>Cohain</surname><given-names>A</given-names></name><name><surname>Pandey</surname><given-names>G</given-names></name><name><surname>Leboeuf</surname><given-names>M</given-names></name><name><surname>Elpek</surname><given-names>KG</given-names></name><name><surname>Helft</surname><given-names>J</given-names></name><name><surname>Hashimoto</surname><given-names>D</given-names></name><name><surname>Chow</surname><given-names>A</given-names></name><name><surname>Price</surname><given-names>J</given-names></name><name><surname>Greter</surname><given-names>M</given-names></name><name><surname>Bogunovic</surname><given-names>M</given-names></name><name><surname>Bellemare-Pelletier</surname><given-names>A</given-names></name><name><surname>Frenette</surname><given-names>PS</given-names></name><name><surname>Randolph</surname><given-names>GJ</given-names></name><name><surname>Turley</surname><given-names>SJ</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><collab>Immunological Genome Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Deciphering the transcriptional network of the dendritic cell lineage</article-title><source>Nature Immunology</source><volume>13</volume><fpage>888</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1038/ni.2370</pub-id><pub-id pub-id-type="pmid">22797772</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto-Sato</surname><given-names>E</given-names></name><name><surname>Fujimori</surname><given-names>S</given-names></name><name><surname>Ishizaka</surname><given-names>M</given-names></name><name><surname>Hirai</surname><given-names>N</given-names></name><name><surname>Masuoka</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>R</given-names></name><name><surname>Ozawa</surname><given-names>Y</given-names></name><name><surname>Hino</surname><given-names>K</given-names></name><name><surname>Washio</surname><given-names>T</given-names></name><name><surname>Tomita</surname><given-names>M</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Oshikubo</surname><given-names>T</given-names></name><name><surname>Akasaka</surname><given-names>H</given-names></name><name><surname>Sugiyama</surname><given-names>J</given-names></name><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Yanagawa</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A comprehensive resource of interacting protein regions for refining human transcription factor networks</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e9289</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0009289</pub-id><pub-id pub-id-type="pmid">20195357</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naba</surname><given-names>A</given-names></name><name><surname>Clauser</surname><given-names>KR</given-names></name><name><surname>Hoersch</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Carr</surname><given-names>SA</given-names></name><name><surname>Hynes</surname><given-names>RO</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>11</volume><elocation-id>M111</elocation-id><pub-id pub-id-type="doi">10.1074/mcp.M111.014647</pub-id><pub-id pub-id-type="pmid">22159717</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nejjari</surname><given-names>M</given-names></name><name><surname>Couvelard</surname><given-names>A</given-names></name><name><surname>Mosnier</surname><given-names>JF</given-names></name><name><surname>Moreau</surname><given-names>A</given-names></name><name><surname>Feldmann</surname><given-names>G</given-names></name><name><surname>Degott</surname><given-names>C</given-names></name><name><surname>Marcellin</surname><given-names>P</given-names></name><name><surname>Scoazec</surname><given-names>JY</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Integrin up-regulation in chronic liver disease: relationship with inflammation and fibrosis in chronic hepatitis C</article-title><source>The Journal of Pathology</source><volume>195</volume><fpage>473</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1002/path.964</pub-id><pub-id pub-id-type="pmid">11745680</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishio</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>R</given-names></name><name><surname>Koyama</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Rosenthal</surname><given-names>SB</given-names></name><name><surname>Yamamoto</surname><given-names>G</given-names></name><name><surname>Karin</surname><given-names>D</given-names></name><name><surname>Baglieri</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>H-Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Dhar</surname><given-names>D</given-names></name><name><surname>Iwaisako</surname><given-names>K</given-names></name><name><surname>Taura</surname><given-names>K</given-names></name><name><surname>Brenner</surname><given-names>DA</given-names></name><name><surname>Kisseleva</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice</article-title><source>Journal of Hepatology</source><volume>71</volume><fpage>573</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.04.012</pub-id><pub-id pub-id-type="pmid">31071368</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>L</given-names></name><name><surname>Geyer</surname><given-names>PE</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Santos</surname><given-names>A</given-names></name><name><surname>Meier</surname><given-names>F</given-names></name><name><surname>Doll</surname><given-names>S</given-names></name><name><surname>Wewer Albrechtsen</surname><given-names>NJ</given-names></name><name><surname>Klein</surname><given-names>S</given-names></name><name><surname>Ortiz</surname><given-names>C</given-names></name><name><surname>Uschner</surname><given-names>FE</given-names></name><name><surname>Schierwagen</surname><given-names>R</given-names></name><name><surname>Trebicka</surname><given-names>J</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Dynamic human liver proteome atlas reveals functional insights into disease pathways</article-title><source>Molecular Systems Biology</source><volume>18</volume><elocation-id>e10947</elocation-id><pub-id pub-id-type="doi">10.15252/msb.202210947</pub-id><pub-id pub-id-type="pmid">35579278</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ojha</surname><given-names>S</given-names></name><name><surname>Pribyl</surname><given-names>J</given-names></name><name><surname>Klimovic</surname><given-names>S</given-names></name><name><surname>Hadraba</surname><given-names>D</given-names></name><name><surname>Jirouskova</surname><given-names>M</given-names></name><name><surname>Gregor</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Measurement of liver stiffness using atomic force microscopy coupled with polarization microscopy</article-title><source>Journal of Visualized Experiments</source><volume>01</volume><elocation-id>e974</elocation-id><pub-id pub-id-type="doi">10.3791/63974</pub-id><pub-id pub-id-type="pmid">35938823</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsen</surname><given-names>AL</given-names></name><name><surname>Bloomer</surname><given-names>SA</given-names></name><name><surname>Chan</surname><given-names>EP</given-names></name><name><surname>Gaça</surname><given-names>MDA</given-names></name><name><surname>Georges</surname><given-names>PC</given-names></name><name><surname>Sackey</surname><given-names>B</given-names></name><name><surname>Uemura</surname><given-names>M</given-names></name><name><surname>Janmey</surname><given-names>PA</given-names></name><name><surname>Wells</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hepatic stellate cells require a stiff environment for myofibroblastic differentiation</article-title><source>American Journal of Physiology. Gastrointestinal and Liver Physiology</source><volume>301</volume><fpage>G110</fpage><lpage>G118</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00412.2010</pub-id><pub-id pub-id-type="pmid">21527725</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsen</surname><given-names>AL</given-names></name><name><surname>Sackey</surname><given-names>BK</given-names></name><name><surname>Marcinkiewicz</surname><given-names>C</given-names></name><name><surname>Boettiger</surname><given-names>D</given-names></name><name><surname>Wells</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fibronectin extra domain-A promotes hepatic stellate cell motility but not differentiation into myofibroblasts</article-title><source>Gastroenterology</source><volume>142</volume><fpage>928</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2011.12.038</pub-id><pub-id pub-id-type="pmid">22202457</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Riverol</surname><given-names>Y</given-names></name><name><surname>Bandla</surname><given-names>C</given-names></name><name><surname>Kundu</surname><given-names>DJ</given-names></name><name><surname>Kamatchinathan</surname><given-names>S</given-names></name><name><surname>Bai</surname><given-names>J</given-names></name><name><surname>Hewapathirana</surname><given-names>S</given-names></name><name><surname>John</surname><given-names>NS</given-names></name><name><surname>Prakash</surname><given-names>A</given-names></name><name><surname>Walzer</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Vizcaíno</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>The PRIDE database at 20 years: 2025 update</article-title><source>Nucleic Acids Research</source><volume>53</volume><fpage>D543</fpage><lpage>D553</lpage><pub-id pub-id-type="doi">10.1093/nar/gkae1011</pub-id><pub-id pub-id-type="pmid">39494541</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popov</surname><given-names>Y</given-names></name><name><surname>Patsenker</surname><given-names>E</given-names></name><name><surname>Stickel</surname><given-names>F</given-names></name><name><surname>Zaks</surname><given-names>J</given-names></name><name><surname>Bhaskar</surname><given-names>KR</given-names></name><name><surname>Niedobitek</surname><given-names>G</given-names></name><name><surname>Kolb</surname><given-names>A</given-names></name><name><surname>Friess</surname><given-names>H</given-names></name><name><surname>Schuppan</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies</article-title><source>Journal of Hepatology</source><volume>48</volume><fpage>453</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2007.11.021</pub-id><pub-id pub-id-type="pmid">18221819</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramachandran</surname><given-names>P</given-names></name><name><surname>Dobie</surname><given-names>R</given-names></name><name><surname>Wilson-Kanamori</surname><given-names>JR</given-names></name><name><surname>Dora</surname><given-names>EF</given-names></name><name><surname>Henderson</surname><given-names>BEP</given-names></name><name><surname>Luu</surname><given-names>NT</given-names></name><name><surname>Portman</surname><given-names>JR</given-names></name><name><surname>Matchett</surname><given-names>KP</given-names></name><name><surname>Brice</surname><given-names>M</given-names></name><name><surname>Marwick</surname><given-names>JA</given-names></name><name><surname>Taylor</surname><given-names>RS</given-names></name><name><surname>Efremova</surname><given-names>M</given-names></name><name><surname>Vento-Tormo</surname><given-names>R</given-names></name><name><surname>Carragher</surname><given-names>NO</given-names></name><name><surname>Kendall</surname><given-names>TJ</given-names></name><name><surname>Fallowfield</surname><given-names>JA</given-names></name><name><surname>Harrison</surname><given-names>EM</given-names></name><name><surname>Mole</surname><given-names>DJ</given-names></name><name><surname>Wigmore</surname><given-names>SJ</given-names></name><name><surname>Newsome</surname><given-names>PN</given-names></name><name><surname>Weston</surname><given-names>CJ</given-names></name><name><surname>Iredale</surname><given-names>JP</given-names></name><name><surname>Tacke</surname><given-names>F</given-names></name><name><surname>Pollard</surname><given-names>JW</given-names></name><name><surname>Ponting</surname><given-names>CP</given-names></name><name><surname>Marioni</surname><given-names>JC</given-names></name><name><surname>Teichmann</surname><given-names>SA</given-names></name><name><surname>Henderson</surname><given-names>NC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Resolving the fibrotic niche of human liver cirrhosis at single-cell level</article-title><source>Nature</source><volume>575</volume><fpage>512</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1631-3</pub-id><pub-id pub-id-type="pmid">31597160</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rappsilber</surname><given-names>J</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name><name><surname>Ishihama</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips</article-title><source>Nature Protocols</source><volume>2</volume><fpage>1896</fpage><lpage>1906</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.261</pub-id><pub-id pub-id-type="pmid">17703201</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reed</surname><given-names>NI</given-names></name><name><surname>Jo</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Tsujino</surname><given-names>K</given-names></name><name><surname>Arnold</surname><given-names>TD</given-names></name><name><surname>DeGrado</surname><given-names>WF</given-names></name><name><surname>Sheppard</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The αvβ1 integrin plays a critical in vivo role in tissue fibrosis</article-title><source>Science Translational Medicine</source><volume>7</volume><elocation-id>288ra79</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaa5094</pub-id><pub-id pub-id-type="pmid">25995225</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saneyasu</surname><given-names>T</given-names></name><name><surname>Akhtar</surname><given-names>R</given-names></name><name><surname>Sakai</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Molecular cues guiding matrix stiffness in liver fibrosis</article-title><source>BioMed Research International</source><volume>2016</volume><elocation-id>2646212</elocation-id><pub-id pub-id-type="doi">10.1155/2016/2646212</pub-id><pub-id pub-id-type="pmid">27800489</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiller</surname><given-names>HB</given-names></name><name><surname>Fernandez</surname><given-names>IE</given-names></name><name><surname>Burgstaller</surname><given-names>G</given-names></name><name><surname>Schaab</surname><given-names>C</given-names></name><name><surname>Scheltema</surname><given-names>RA</given-names></name><name><surname>Schwarzmayr</surname><given-names>T</given-names></name><name><surname>Strom</surname><given-names>TM</given-names></name><name><surname>Eickelberg</surname><given-names>O</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Time- and compartment-resolved proteome profiling of the extracellular niche in lung injury and repair</article-title><source>Molecular Systems Biology</source><volume>11</volume><elocation-id>819</elocation-id><pub-id pub-id-type="doi">10.15252/msb.20156123</pub-id><pub-id pub-id-type="pmid">26174933</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuppan</surname><given-names>D</given-names></name><name><surname>Cramer</surname><given-names>T</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Strefeld</surname><given-names>T</given-names></name><name><surname>Hahn</surname><given-names>EG</given-names></name><name><surname>Herbst</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Hepatocytes as a source of collagen type XVIII endostatin</article-title><source>Lancet</source><volume>352</volume><fpage>879</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)60006-2</pub-id><pub-id pub-id-type="pmid">9742985</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>H-Y</given-names></name><name><surname>Lee</surname><given-names>S-H</given-names></name><name><surname>Lee</surname><given-names>J-H</given-names></name><name><surname>Kang</surname><given-names>YN</given-names></name><name><surname>Choi</surname><given-names>Y-K</given-names></name><name><surname>Hwang</surname><given-names>JS</given-names></name><name><surname>Park</surname><given-names>K-G</given-names></name><name><surname>Jang</surname><given-names>BK</given-names></name><name><surname>Kim</surname><given-names>M-K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Clusterin attenuates hepatic fibrosis by inhibiting hepatic stellate cell activation and downregulating the smad3 signaling pathway</article-title><source>Cells</source><volume>8</volume><elocation-id>1442</elocation-id><pub-id pub-id-type="doi">10.3390/cells8111442</pub-id><pub-id pub-id-type="pmid">31739636</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>X</given-names></name><name><surname>Taha</surname><given-names>IN</given-names></name><name><surname>Clauser</surname><given-names>KR</given-names></name><name><surname>Gao</surname><given-names>YT</given-names></name><name><surname>Naba</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>MatrisomeDB: the ECM-protein knowledge database</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>D1136</fpage><lpage>D1144</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz849</pub-id><pub-id pub-id-type="pmid">31586405</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shim</surname><given-names>Y-J</given-names></name><name><surname>Kang</surname><given-names>B-H</given-names></name><name><surname>Jeon</surname><given-names>H-S</given-names></name><name><surname>Park</surname><given-names>I-S</given-names></name><name><surname>Lee</surname><given-names>K-U</given-names></name><name><surname>Lee</surname><given-names>I-K</given-names></name><name><surname>Park</surname><given-names>G-H</given-names></name><name><surname>Lee</surname><given-names>K-M</given-names></name><name><surname>Schedin</surname><given-names>P</given-names></name><name><surname>Min</surname><given-names>B-H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Clusterin induces matrix metalloproteinase-9 expression via ERK1/2 and PI3K/Akt/NF-κB pathways in monocytes/macrophages</article-title><source>Journal of Leukocyte Biology</source><volume>90</volume><fpage>761</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1189/jlb.0311110</pub-id><pub-id pub-id-type="pmid">21742938</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sottile</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>F</given-names></name><name><surname>Rublyevska</surname><given-names>I</given-names></name><name><surname>Chiang</surname><given-names>H-Y</given-names></name><name><surname>Lust</surname><given-names>J</given-names></name><name><surname>Chandler</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Fibronectin-dependent collagen I deposition modulates the cell response to fibronectin</article-title><source>American Journal of Physiology. Cell Physiology</source><volume>293</volume><fpage>C1934</fpage><lpage>C1946</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00130.2007</pub-id><pub-id pub-id-type="pmid">17928541</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>N</given-names></name><name><surname>Geng</surname><given-names>D</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Bai</surname><given-names>X</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>X-H</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Liver cancer heterogeneity modeled by in situ genome editing of hepatocytes</article-title><source>Science Advances</source><volume>8</volume><elocation-id>eabn5683</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abn5683</pub-id><pub-id pub-id-type="pmid">35731873</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trautwein</surname><given-names>C</given-names></name><name><surname>Friedman</surname><given-names>SL</given-names></name><name><surname>Schuppan</surname><given-names>D</given-names></name><name><surname>Pinzani</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Hepatic fibrosis: Concept to treatment</article-title><source>Journal of Hepatology</source><volume>62</volume><fpage>S15</fpage><lpage>S24</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2015.02.039</pub-id><pub-id pub-id-type="pmid">25920084</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyanova</surname><given-names>S</given-names></name><name><surname>Temu</surname><given-names>T</given-names></name><name><surname>Sinitcyn</surname><given-names>P</given-names></name><name><surname>Carlson</surname><given-names>A</given-names></name><name><surname>Hein</surname><given-names>MY</given-names></name><name><surname>Geiger</surname><given-names>T</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name><name><surname>Cox</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The Perseus computational platform for comprehensive analysis of (prote)omics data</article-title><source>Nature Methods</source><volume>13</volume><fpage>731</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3901</pub-id><pub-id pub-id-type="pmid">27348712</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>LM</given-names></name><name><surname>McCann</surname><given-names>FE</given-names></name><name><surname>Cabrita</surname><given-names>MA</given-names></name><name><surname>Layton</surname><given-names>T</given-names></name><name><surname>Cribbs</surname><given-names>A</given-names></name><name><surname>Knezevic</surname><given-names>B</given-names></name><name><surname>Fang</surname><given-names>H</given-names></name><name><surname>Knight</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>R</given-names></name><name><surname>Bonham</surname><given-names>S</given-names></name><name><surname>Steenbeek</surname><given-names>LM</given-names></name><name><surname>Yang</surname><given-names>N</given-names></name><name><surname>Sood</surname><given-names>M</given-names></name><name><surname>Bainbridge</surname><given-names>C</given-names></name><name><surname>Warwick</surname><given-names>D</given-names></name><name><surname>Harry</surname><given-names>L</given-names></name><name><surname>Davidson</surname><given-names>D</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Sundstrӧm</surname><given-names>M</given-names></name><name><surname>Feldmann</surname><given-names>M</given-names></name><name><surname>Nanchahal</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300</article-title><source>PNAS</source><volume>117</volume><fpage>20753</fpage><lpage>20763</lpage><pub-id pub-id-type="doi">10.1073/pnas.2004281117</pub-id><pub-id pub-id-type="pmid">32759223</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>MR</given-names></name><name><surname>Zoubeidi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Clusterin as a therapeutic target</article-title><source>Expert Opinion on Therapeutic Targets</source><volume>21</volume><fpage>201</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1080/14728222.2017.1267142</pub-id><pub-id pub-id-type="pmid">27978767</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Qiao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zeng</surname><given-names>R</given-names></name><name><surname>Ge</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dynamically remodeled hepatic extracellular matrix predicts prognosis of early-stage cirrhosis</article-title><source>Cell Death &amp; Disease</source><volume>12</volume><elocation-id>163</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-021-03443-y</pub-id><pub-id pub-id-type="pmid">33558482</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Kwon</surname><given-names>J</given-names></name><name><surname>Popov</surname><given-names>Y</given-names></name><name><surname>Gajdos</surname><given-names>GB</given-names></name><name><surname>Ordog</surname><given-names>T</given-names></name><name><surname>Brekken</surname><given-names>RA</given-names></name><name><surname>Mukhopadhyay</surname><given-names>D</given-names></name><name><surname>Schuppan</surname><given-names>D</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Simonetto</surname><given-names>D</given-names></name><name><surname>Shah</surname><given-names>VH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Vascular endothelial growth factor promotes fibrosis resolution and repair in mice</article-title><source>Gastroenterology</source><volume>146</volume><fpage>1339</fpage><lpage>1350</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2014.01.061</pub-id><pub-id pub-id-type="pmid">24503129</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Su</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Niu</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Single-cell transcriptomic analysis reveals a hepatic stellate cell-activation roadmap and myofibroblast origin during liver fibrosis in mice</article-title><source>Hepatology</source><volume>74</volume><fpage>2774</fpage><lpage>2790</lpage><pub-id pub-id-type="doi">10.1002/hep.31987</pub-id><pub-id pub-id-type="pmid">34089528</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>H-Y</given-names></name><name><surname>Yin</surname><given-names>C</given-names></name><name><surname>Hou</surname><given-names>J-L</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y-X</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>P-F</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Tan</surname><given-names>Y-X</given-names></name><name><surname>Zhang</surname><given-names>J-P</given-names></name><name><surname>Ning</surname><given-names>B-F</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H-Y</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>W-F</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Hepatocyte nuclear factor 4alpha attenuates hepatic fibrosis in rats</article-title><source>Gut</source><volume>59</volume><fpage>236</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1136/gut.2008.174904</pub-id><pub-id pub-id-type="pmid">19671543</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98023.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mistry</surname><given-names>Pramod K</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> study suggests that the composition of the extracellular matrix in a mouse model of liver fibrosis changes depending on the cause of liver fibrosis. The data could be used as a foundation for future antifibrotic therapies. The strength of evidence is <bold>convincing</bold> with respect to the use of animal models and proteomic analysis. The study provides a helpful inventory of proteins up or down-regulated.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98023.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Jirouskova and colleagues in their study have carried out an in depth proteomic characterization of the dynamics of the liver fibrotic response and the resulting resolution in two distinct models of liver injury: CCl4-induced model of hepatotoxicity and pericentral/bridging liver fibrosis and the DDC feeding model of obstructive cholestasis and periportal fibrosis. They focussed on both the insoluble extracellular matrix (ECM) components as well as the soluble secreted factors produced by hepatic stellate cells (HSCs) and/or portal fibroblasts (PFs). They identified compartment- and time-resolved proteomic signatures in the two models with disease-specific factors or matrisomes. Their study also identified phenotypic differences between the models such as that while the CCl4-induced model induced profound hepatotoxicity followed by resolution, the DDC model induced more lasting liver damage and proteomic changes that resembled advanced human liver fibrosis favouring hepatocarcinogenesis.</p><p>Overall, this comprehensive and very well conducted study is rigorous and well planned. The conclusions are supported by compelling studies and analyses. One caveat is the lack of mechanistic experiments to prove causality, but this can be carried out in follow-up studies.</p><p>Strengths:</p><p>• A major strength in the study is that the experiments are rigorous and very well conducted. For instance, the authors utilized two models of liver fibrosis to study different aspects of the pathology - hepatotoxicity vs cholestasis. In addition, 4 time points for each model were investigated - 2 for fibrosis development and 2 for fibrosis resolution. They have taken 3 components for proteomic analyses - total lysates, insoluble ECM components as well as the soluble secreted factors. Thus, the authors provide a comprehensive overview of the fibrosis and resolution process in these models.</p><p>• Another great strength of the study is that the methodology utilized was able to dissect unique pathways relevant for each model as well as common targets. For example, the authors identified known pathways such as mTOR signalling to be differentially regulated in the CCl4 vs DDC model. mTOR signalling was increased in the DDC model that is associated with hyperproliferation. Thus showing that the approach taken is specific enough to distinguish between the two similar (both induce fibrosis) but distinct mechanisms (hepatotoxicity vs cholestasis) is a strong point of the study.</p><p>Weaknesses:</p><p>• A caveat of the study is that the authors have not conducted mechanistic (gain of function/loss of function) studies from any of their identified targets to truly prove causality. This remains one of the limitations of this study. Thus, future studies should investigate this point in detail. For instance, it would have been intriguing to dissect if knocking out specific genes involved in one specific model or genes common to both would yield distinct phenotypic outcomes.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98023.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors suggest that ECM abundance and composition change depending on the aetiology of liver fibrosis. To understand this they have investigated the proteome in two models of animal fibrosis and resolution. They suggest their findings could provide a foundation for future anti-fibrotic therapies.</p><p>The revised version has been improved. Although some areas remain (described below), it is perhaps the dataset that will be most valuable.</p><p>Strengths:</p><p>The dataset appears well supported and will be valuable.</p><p>Weaknesses:</p><p>The manuscript is still fairly descriptive but on balance this is a useful dataset and appears to have broad support in that regard.</p><p>There are no conclusions that can be drawn from their rebuttal regarding the human data they included as it is one patient per group and will most likely change dramatically with more patients. As such this area is still an issue but they have improved some of the data elsewhere.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.98023.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jirouskova</surname><given-names>Marketa</given-names></name><role specific-use="author">Author</role><aff><institution>Laboratory of Integrative Biology, Institute of Molecular Genetics of the Czech Academy of Sciences</institution><addr-line><named-content content-type="city">Moscow</named-content></addr-line><country>Czech Republic</country></aff></contrib><contrib contrib-type="author"><name><surname>Harant</surname><given-names>Karel</given-names></name><role specific-use="author">Author</role><aff><institution>Proteomics Core Facility</institution><addr-line><named-content content-type="city">prague</named-content></addr-line><country>Czech Republic</country></aff></contrib><contrib contrib-type="author"><name><surname>Cejnar</surname><given-names>Pavel</given-names></name><role specific-use="author">Author</role><aff><institution>Department of Mathematics</institution><addr-line><named-content content-type="city">Prague</named-content></addr-line><country>Czech Republic</country></aff></contrib><contrib contrib-type="author"><name><surname>Ojha</surname><given-names>Srikant</given-names></name><role specific-use="author">Author</role><aff><institution>Laboratory of Integrative Biology, Institute of Molecular Genetics of the Czech Academy of Sciences</institution><addr-line><named-content content-type="city">Moscow</named-content></addr-line><country>Czech Republic</country></aff></contrib><contrib contrib-type="author"><name><surname>Korelova</surname><given-names>Katerina</given-names></name><role specific-use="author">Author</role><aff><institution>Laboratory of Integrative Biology, Institute of Molecular Genetics of the Czech Academy of Sciences</institution><addr-line><named-content content-type="city">Moscow</named-content></addr-line><country>Czech Republic</country></aff></contrib><contrib contrib-type="author"><name><surname>Sarnova</surname><given-names>Lenka</given-names></name><role specific-use="author">Author</role><aff><institution>Laboratory of Integrative Biology, Institute of Molecular Genetics of the Czech Academy of Sciences</institution><addr-line><named-content content-type="city">Moscow</named-content></addr-line><country>Czech Republic</country></aff></contrib><contrib contrib-type="author"><name><surname>Sticova</surname><given-names>Eva</given-names></name><role specific-use="author">Author</role><aff><institution>Clinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine</institution><addr-line><named-content content-type="city">Prague</named-content></addr-line><country>Czech Republic</country></aff></contrib><contrib contrib-type="author"><name><surname>Mayr</surname><given-names>Christoph H</given-names></name><role specific-use="author">Author</role><aff><institution>Comprehensive Pneumology Center (CPC)/Institute of Lung Health and Immunity (LHI), Helmholtz Munich; Member of the German Center for Lung Research (DZL)</institution><addr-line><named-content content-type="city">Munich</named-content></addr-line><country>Germany</country></aff></contrib><contrib contrib-type="author"><name><surname>Schiller</surname><given-names>Herbert</given-names></name><role specific-use="author">Author</role><aff><institution>Helmholtz Munich</institution><addr-line><named-content content-type="city">Munich</named-content></addr-line><country>Germany</country></aff></contrib><contrib contrib-type="author"><name><surname>Gregor</surname><given-names>Martin</given-names></name><role specific-use="author">Author</role><aff><institution>Laboratory of Integrative Biology, Institute of Molecular Genetics of the Czech Academy of Sciences</institution><addr-line><named-content content-type="city">Moscow</named-content></addr-line><country>Czech Republic</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1:</bold></p><p>Weaknesses:</p><p>(1) The authors themselves propose in their Introduction that the &quot;ECM-associated changes are increasingly perceived as causative, rather than consequential&quot;; however, they have not conducted mechanistic (gain of function/loss of function) studies either in vitro or in vivo from any of their identified targets to truly prove causality. This remains one of the limitations of this study. Thus, future studies should investigate this point in detail. For instance, it would have been intriguing to dissect if knocking out specific genes involved in one specific model or genes common to both would yield distinct phenotypic outcomes.</p></disp-quote><p>We agree with the reviewer that our study does not provide mechanistic verification of the function of identified targets with suggested role in the development and/or resolution of fibrosis. The current study was primarily conducted in order to identify these possible targets with focus on the identification of differences in extracellular matrix deposited in two selected models of liver fibrosis with different modes of action. To conduct further studies using knock-out/in models for verification of causality of proposed targets was at this point well beyond our intention. However, we are fully aware of the potential of identified molecules and further studies to disect their roles in liver diseases are part of future plans.</p><disp-quote content-type="editor-comment"><p>(2) The majority of the conclusions are derived primarily from the proteomic analyses. Although well conducted, it would strengthen the study to corroborate some of the major findings by other means such as IHC/IF with the corresponding quantifications and not only representative images.</p></disp-quote><p>We have now provided additional IF images and their quantifications in accordance with the Reviewer’s suggestions to our major MS findings to strenghten the significance of the MS data (see detailed answer below).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2:</bold></p><p>Weaknesses:</p><p>(1) As it currently stands, the data, whilst extensive, is primarily focussed on the proteomic data which is fairly descriptive and I am not clear on the additional insight gained in their approach that is not already detailed from the extensive transcriptomic studies. The manuscript overall would benefit from some mechanistic functional insight to provide new additional modes of action relevant to fibrosis progression.</p></disp-quote><p>We agree with the reviewer that our study could initially appear descriptive. However, this characteristics is inherent to most omics studies, which tend to provide hypothesis-free testing of a large number of analytes in order to find a multitude of candidate biomarkers(1). Importantly, we believe our study provides insights that go beyond the scope of previously published transcriptomic analyses.</p><p>Specifically, our work focuses on compartment-specific changes in the liver proteome, with an emphasis on the extracellular matrix (ECM) composition and alterations in protein solubility—features that cannot be captured by transcriptomic studies. The matrisome is more than a structural scaffold; it functions as a reservoir for secreted factors, including growth factors and cytokines, which modulate the local cellular microenvironment. Transition dynamics between the insoluble matrisome and soluble protein pools influence the signaling capabilities and bioavailability of these factors. Moreover, fibrous ECM assemblies directly impact tissue mechanics, providing cells embedded within the matrix with spatially distinct biochemical and biomechanical contexts. The current understanding of matrisome composition in the context of specific liver disease etiologies is limited. Dr. Friedman, in his 2022 review on hepatic fibrosis, highlights the unmet need to elucidate etiology-specific protein signatures of the cirrhotic liver matrisome, which could serve as disease staging or prognostic biomarkers(2). Our study addresses this gap by characterizing the distinct matrisome profiles associated with hepatotoxic- versus cholestasis-driven liver injury. We believe our findings lay the groundwork for identifying etiology-specific biomarkers and potential therapeutic targets for antifibrotic interventions, offering a novel layer of insight beyond what transcriptomic data alone can provide.</p><disp-quote content-type="editor-comment"><p>(2) Whilst there is some human data presented it is a minimal analysis without quantification that would imply relevance to disease state. Although studying disease progression in animals is a fundamental aspect of understanding the full physiological response of fibrotic disease, without more human insight makes any analysis difficult to fulfil their suggestion that these targets identified will be of use to treat human disease.</p></disp-quote><p>We thank the reviewer for this comment. Our study primarily focuses on utilizing animal models to explore the fundamental physiological processes underlying the development and resolution of fibrotic liver disease. To address the translational relevance of our findings, we concentrated on clusterin, one of the key target proteins identified during our analysis of the insoluble proteome. Specifically, we investigated its localization in human liver samples, focusing on its association with collagen deposits (Figure 6F). To this end, we analyzed human liver samples of diverse etiologies and varying degrees of fibrotic damage, including samples representing four distinct stages of HCV-induced fibrosis (Figure 6F, lower panel). While this analysis highlights the presence and localization of clusterin in fibrotic deposits, we acknowledge that our study does not include extensive quantification or mechanistic insight into clusterin's role in human liver fibrosis. We believe that the data presented in this manuscript provide a valuable foundation for future investigations into clusterin’s involvement in liver fibrosis across different etiologies. Recognizing the translational importance of this work, we have already initiated a prospective study involving human patients, which aims to conduct a more comprehensive analysis of clusterin's function and its potential as a therapeutic target.</p><p>To further support our findings on clusterin's role in fibrosis development and resolution and to address the reviewer's concern, we quantified clusterin deposits in the available human samples representing four distinct stages of HCV-induced fibrotic disease. Using immunofluorescence (IF) images at a 20x field of view, we measured both clusterin and collagen deposits to illustrate changes in clusterin abundance during fibrosis progression (stages F1–F4) in relation to collagen deposition dynamics. The quantified data have been included for the reviewer's consideration (Figure 1). However, it is important to emphasize that this quantification was conducted on a single human sample per fibrotic stage, which limits the statistical robustness of the analysis. A more comprehensive evaluation involving additional patient samples would be necessary for a more definitive conclusion. For this reason, we propose to include these results solely in our rebuttal letter and to incorporate a more extensive analysis in our intended follow-up study, where larger cohorts will allow for a thorough investigation of clusterin's role in human liver fibrosis.</p><fig id="sa3fig1" position="float"><label>Author response image 1.</label><caption><title>Dynamics of clusterin abundance with the development of HCV-induced fibrotic disease in comparison to the changes in collagen deposits.</title><p>IF images of human liver sections from different stages of chronic HCV infection were immunolabeled for clusterin and collagen 1. Clusterin- and collagenpositive (<sup>+</sup>) areas (as %) from three to eight fields of view (20x objective) were evaluated for each fibrosis stage (F1-F4).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-98023-sa3-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(3) Some of the terminology is incorrect while discussing these models of injury used and care should be taken. For example - both models are toxin-induced and I do not think these data have any support that the DDC model has a higher carcinogenic risk. An investigation into the tumour-induced risk would require significant additional models. These types of statements are incorrect and not supported by this study.</p></disp-quote><p>We are grateful to the reviewer for drawing our attention to the incorrect use of the term &quot;toxin-induced&quot;. In two instances, where the wording was incorrect, we have corrected the term to hepatotoxin-induced as it was originally intended. While we believe that our proteomic signature data and identified signaling pathways suggest a potential carcinogenic risk associated with the cholestatic, but not the hepatotoxic model, we have toned down the statements on this issue in the article to respect the reviewer's perspective. These changes, which are highlighted in the track changes mode of the article, aim to make the conclusions of the study more precise and thus improve the clarity of our conclusions.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>(1) In the Discussion, the authors could consider pointing out that one limitation of the study is a lack of mechanistic (gain of function/loss of function) studies either in vitro or in vivo from any of their identified targets to truly prove causality.</p></disp-quote><p>As noted earlier, we fully agree with both reviewers that a limitation of this study is its descriptive nature, which is an inherent characteristic of omics-based research. In our manuscript, we aimed to &quot;determine compartment-specific proteomic landscapes of liver fibrosis and delineate etiology-specific ECM components,&quot; with the overarching goal of providing a foundation for future antifibrotic therapies.</p><p>The insights gained from our study will indeed serve as a critical basis for subsequent research, where we will prioritize mechanistic investigations to elucidate the roles of the identified targets. While we acknowledge the importance of gain- or loss-of-function studies to establish causality, we believe this falls outside the primary scope of the current manuscript. Instead, we envision these mechanistic approaches as key elements of our future research efforts. For this reason, we feel it is not necessary to further expand on this limitation in the current discussion.</p><disp-quote content-type="editor-comment"><p>(2) The majority of the conclusions are derived primarily from the proteomic analyses. Although well conducted, it would strengthen the study to corroborate some of the major findings by other means such as IHC/IF with the corresponding quantifications and not only representative images. For example, the IF stainings for ECM1 should also be quantified - ECM1.</p></disp-quote><p>To strengthen our MS findings on ECM1 expression and to address the reviewer's concern, we have now included quantification of ECM1 using IF staining at selected time points in Figure S7E and we refer to these data in the Results section (p. 12 of the current manuscript). The IF quantification data correspond well to the MS data showing increase in ECM1 expression with fibrosis development and decline with partial fibrosis resolution.</p><disp-quote content-type="editor-comment"><p>(3) S1 - it would be important to show Sirius Red images over the time course, especially for CCl4 T4 where fibrosis resolution is occurring. Proteomics data also show this group clusters more closely with control mice and seeing a representative image would add further credibility to this point.</p></disp-quote><p>Requsted Sirius Red images are now part of the Figure S1B, documenting partial fibrosis resolution and overall parenchyma healing in T4 in both models.</p><disp-quote content-type="editor-comment"><p>(4) How comparable are the periods of the two models? 2 weeks in one model may not be the same as 2 weeks in the other depending on the severity of the pathogenesis.</p></disp-quote><p>We appreciate the reviewer’s comment regarding the comparability of time points between the two models. Indeed, the temporal dynamics of fibrosis development differ between the models employed in our study, and we have carefully considered this aspect to ensure the validity of our comparative analysis. To address this, we started our comparisons at a stage corresponding to the onset of fibrosis in each model. Specifically, quantification of Sirius Red-positive areas, indicative of collagen deposition (Figure S1B), revealed that 2 weeks of DDC treatment produced a comparable extent of fibrosis to that observed after 3 weeks of CCl₄ treatment. This point was designated as the initial fibrosis time point (T1, Figure S1B), from which further treatment was applied to induce more advanced fibrosis. This approach allowed us to standardize the comparison of fibrosis progression between the two models.</p><disp-quote content-type="editor-comment"><p>(5) Figure 4A-D - cell-type-specific signatures should be corroborated by actual IHC or IF stainings if possible. HNF4a (hepatocytes), CK19 (cholangiocytes), aSMA (activated fibrogenic HSCs), immune cells (B220, F4/80, Cd11b, CD11c etc).</p></disp-quote><p>We thank the reviewer for this valuable suggestion. To strengthen our analysis, we have now complemented the box plots of cell type-specific signatures derived from the MS data (Figure 4A-D) with immunofluorescence (IF) staining, which has been included in the Supplemental Data (Figure S6). Specifically, we provide representative IF images from control and T1-T4 time points for each model, documenting the changes in abundance with treatment in:</p><p>A) Hepatocytes (HNF4α), activated hepatic stellate cells (αSMA), and cholangiocytes (CK19).</p><p>B) Immune cell populations, including B cells (B220) and macrophages/monocytes/Kupffer cells (F4/80), as these immune cell groups were not only identified in our MS analysis but also have established roles in the selected models(3, 4, 5).</p><p>The representative images shown in Figure S6 show the dynamics of the cellular populations in each of the models, which correspond well with the MS data (compare Figures 4A-D and S5). These additional data further validate our findings and enhance the robustness of our conclusions.</p><p>References:</p><p>(1) Thiele M, Villesen IF, Niu L, et al. Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases. J Hepatol 2024;81:345-359.</p><p>(2) Friedman SL, Pinzani M. Hepatic fibrosis 2022: Unmet needs and a blueprint for the future. Hepatology 2022;75:473-488.</p><p>(3) Best J, Verhulst S, Syn WK, et al. Macrophage Depletion Attenuates Extracellular Matrix Deposition and Ductular Reaction in a Mouse Model of Chronic Cholangiopathies. PLoS One 2016;11:e0162286.</p><p>(4) Aoyama T, Inokuchi S, Brenner DA, et al. CX3CL1-CX3CR1 interaction prevents carbon tetrachlorideinduced liver inflammation and fibrosis in mice. Hepatology 2010;52:1390-400.</p><p>(5) Yang W, Chen L, Zhang J, et al. In-Depth Proteomic Analysis Reveals Phenotypic Diversity of Macrophages in Liver Fibrosis. J Proteome Res 2024;23:5166-5176.</p></body></sub-article></article>